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ABSTRACT 
Pericytes are vessel associated mural cells that form the smooth muscle 
layer of vessels. They are able to contribute to skeletal muscle regeneration as 
previously demonstrated for mesoangioblasts that indeed represent their in vitro 
counterpart. Pericytes are a heterogeneous population characterized by different 
marker like Alkaline Phosphatase, Smooth muscle actin, Neuro glial2 (NG2).  
Endothelial cells recruit pericytes from the surrounding mesoderm progenitor 
through a PDGF-PDGFrB loop.  
In this work I have conducted experiments whose results showed that 
functional pericytes may derive from direct reprogramming of already committed 
embryonic and, less frequently, fetal skeletal myoblasts. When co-transplanted 
in vivo with endothelial cells, Pax3 or Myf5 expressing myoblasts, downregulate 
myogenic genes, with the notable exception of Myf5, upregulate pericyte 
markers, adopting a perithelial position and morphology in newly formed vessel 
networks. The activity of endothelial cells can be replaced by exposure to 
PDGF-BB and Dll4 but not Dll1 or Jagged 1, while inhibition of Notch signaling 
via a γ-secretase inhibitor completely restores myogenesis, confirming that the 
skeletal myogenic program is not irreversibly erased.  
Notch activation in MyoD expressing embryonic cells in vivo abolishes 
myogenesis but not Myf5 expression that however cannot activate myogenin 
and trigger myogenesis because Notch, beside suppressing MyoD transcription, 
activates Id and Twist factors that bind to and inhibit Myf5 transcriptional activity. 
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Myf5 expressing cells activate pericyte genes and adopt a perithelial position, a 
phenomenon that can be rarely observed also in WT embryos. 
These data demonstrate that endothelial cells are able to directly 
reprogram committed skeletal myoblasts to mature pericytes for the formation 
and stabilization of vessel wall, suggesting that reprogramming occurs as a 
natural developmental process that leads in a sort of competition between 
endothelium and muscle. 
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INTRODUCTION 
1.1 Pericytes 
1.1.1 Pericyte characteristics and markers 
Although Eberth described their presence in 1871 (Eberth, 1871), the 
discovery of pericytes is commonly assigned to the French scientist Charles-
Marie Benjamin Rouget, who two years later described a population of 
contractile cells surrounding the endothelial cells of small blood vessels 
(Rouget, 1873). Zimmermann later called these cells ‘‘Rouget cells’’ and also 
coined the term ‘‘pericytes,’’ alluding to their location in close proximity to the 
endothelial cells (Zimmermann, 1923). Between 1920 and 1950 numerous 
other publications described pericytes, some of them, however, questioning the 
contractility of the cells (reviewed by(Miller and Sims, 1986). Part of these 
discrepancies probably had experimental reasons, but they may also reflect 
pericyte heterogeneity and confusion about cell identity. Today, it is clear that 
different cell types occupy the peri-endothelial compartments, so that their 
correct identification is still challenging (reviewed by(Krueger and Bechmann, 
2010). 
Currently mature pericytes are defined as cells embedded within the 
vascular basement membrane (BM) thanks to the application of electron 
microscopy (reviewed(Miller and Sims, 1986). As discussed below, this 
definition is difficult to apply in situations of active angiogenesis. Another 
commonly accepted defining criterion is their presence in microvessels, i.e., 
capillaries, postcapillary venules, and terminal arterioles. Also, this definition 
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has been challenged by observations of subendothelial pericyte-like cells in 
large vessels (reviewed by(Diaz-Flores et al., 2009). 
The periendothelial location of pericytes is frequently confused with the 
periendothelial location of vascular smooth muscle cells (vSMCs), fibroblasts, 
macrophages, and even epithelial cells which are cells distinct from pericytes. 
Although the field has generally adopted the view that pericytes belong to the 
same lineage and category of cells as vSMCs, it should be remembered that 
there is no single molecular marker known that can be used to unequivocally 
identify pericytes and distinguish them from vSMCs or other mesenchymal 
cells. The multiple markers that are commonly applied are neither specific nor 
stable in their expression. 
PVC can be classified as pericytes, (peri, around; cyte, cell); alternatively 
as vascular mural cells or vascular smooth muscle cells (VSMC) depending on 
their morphology and location.  
Pericytes (as revealed by electron microscopy), possess a prominent 
nucleus and a small content of cytoplasm with several large processes. They 
are found in blood capillaries, pre-capillary arterioles, post-capillary venules, 
and collecting venules. In these vessels, endothelial cells and pericytes share 
the same basal membrane and are closely associated by tight, gap, and 
adherence junctions. Vascular smooth muscle cells are detected around large 
arteries and veins and are separated from the vascular basal membrane by a 
layer of mesenchymal cells and extracellular matrix, the intima. However, it is 
important to remember that distinction between pericytes and VSMC is not 
absolute, both cells may represent subtypes of the related cell type (Armulik et 
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al., 2005; Armulik et al., 2011) or they can derive from the same progenitor. It 
has also been suggested that pericytes may reside subjacent to the 
endothelium of large vessels and be the progenitors of VSMC. 
Pericytes’ distribution is highly variable according to size and to vessel 
type: they are quite abundant on small venules and arterioles but rather sparse 
on capillaries; they cover irregularly the veins with large processes and 
continuously the artery where they form a cell layer. Distribution seems to be 
dependent also on blood pressure levels, indeed in human and horses have 
been demonstrated that they are more abundant further down the torso and the 
legs. 
Pericytes show differences also according to the organ in which they are 
found: they are abundant in CNS (central nervous system), where they interact 
via tight junction with the endothelial cells to create the blood brain barrier 
membrane (BBB) (Ballabh et al., 2004), in kidney (called mesangial cells)  
(Betsholtz et al., 2004) and in the liver (called Itoh cells) (Nakajima et al., 2000). 
All these different characteristics and locations make very difficult a 
universal definition of pericytes; there are several markers that can be used to 
detect these cells, but the expression patterns can change according to 
different tissues, or stage of vascular development. Most of these antigens are 
not specific and can be detected also in other cells types. Moreover not all 
pericytes express all pericytes marker. 
 Some of these markers are cytoskeletal proteins such as Desmin, muscle 
specific class III intermediate filament, and α-smooth muscle actin (SMA). 
Desmin is normally expressed by differentiated skeletal muscle, cardiac and 
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smooth muscle cells, while SMA is known to be present on smooth muscle cells 
or particular kinds of fibroblasts called myofibroblasts (Ronnov-Jessen and 
Petersen, 1996). 
Neuro-glial 2 (NG2) is a chondroitin sulfate proteoglycan expressed on 
pericytes, in particular during angiogenesis and vasculogenesis. The name is 
derived from its expression on glial precursors O-2A; it is used to detect 
immature neural stem cells capable to differentiate into neuron or glia.  It can 
bind the bFGF, PDGF-AA, plasminogen and angiostatin. NG2 knockout mice 
are viable, and neovascularization after damage is compromised (Ozerdem and 
Stallcup, 2004) (Rajantie et al., 2004). 
PDGFR-β (Platelet-Derived Growth Factor Receptor beta) is localized on 
pericytes and it has a crucial role in the recruitment of these cells during 
angiogenesis (Betsholtz, 2004). PDGFR-β deficient mouse embryos were found 
to lack microvascular pericytes and to develop numerous capillary 
microaneurysms (Lindahl et al., 1997). 
Comparison between gene expression profile of wild type and PDGFRβ 
knockout mice, made possible to discover a new marker of pericytes: the 
Regulatory G protein Signalling 5 (RGS-5), a GTPase activating protein Giα and 
Gqα, that is almost absent in PDGFRβ knockout mice (Berger et al., 2005). 
Annexin A5 (Anx5) is a protein involved in apoptosis, but unexpectedly is 
also expressed on perivascular cells and it seems to define a novel 
mesenchymal stem cell population. 
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Alkaline phosphatase (AP) isoenzymes, have been found to be expressed 
on pericytes of skeletal muscle (Grim and Carlson, 1990; Safadi et al., 1991) 
bone and heart (Schultz-Hector, 1993; Schultz-Hector et al., 1993). As 
described below, we have used principally this protein to define pericyte-derived 
cells. 
 
PERICYTE MARKER SYMBOL CELLS TYPE 
EXPRESSING 
MARKER 
COMMENTS REFERENCES 
PDGFR-β(platelet- 
derived growth 
factor receptor-beta) 
Pdgfrb Interstitial 
mesenchymal cells 
during development; 
smooth muscle; in the 
CNS certain neurons 
and neuronal 
progenitors; 
myofibroblasts; 
mesenchymal stem 
cells 
Receptor tyrosine 
kinase; functionally 
involved in pericyte 
recruitment during 
angiogenesis; useful 
marker for brain 
pericytes 
Lindhal et al., 1997 
(Winkler et al., 2010) 
NG2 (chondroitin 
sulfate proteoglycan 
4) 
Cspg4 Developing cartilage, 
bone, muscle; early 
postnatal skin; adult 
skin stem cells; 
adipocytes; vSMCs; 
neuronal progenitors; 
oligodendrocyte 
progenitors 
Integral membrane 
chondroitin sulfate 
proteoglycan; involved 
in pericyte recruitment 
to tumor vasculature 
(Ozerdem et al., 2001) 
(Ruiter et al., 1993) 
(Huang et al., 2010) 
 
CD13 (alanyl 
(membrane) 
aminopeptidase) 
Anpep vSMCs, inflamed and 
tumor endothelium; 
myeloid cells; 
epithelial cells in the 
kidney, gut 
Type II membrane zinc- 
dependent 
metalloprotease; useful 
marker for brain 
pericytes 
(Kunz et al., 1994) 
(Dermietzel and 
Krause, 1991) 
aSMA (alpha-smooth 
muscle actin) 
Acta2 Smooth muscle; 
myofibroblasts; 
myoepithlium 
Structural protein; 
quiescent pericytes do 
not express aSMA 
(e.g., CNS); expression 
in pericytes is 
commonly upregulated 
in tumors and in 
inflammation 
(Nehls and 
Drenckhahn, 1993) 
Desmin Des Skeletal, cardiac, 
smooth muscle 
Structural protein; 
useful pericyte marker 
outside skeletal muscle 
and heart 
(Nehls et al., 1992) 
Table  1.1 Pericyte Marker 
 
1.1.2 Pericyte function and origin 
Pericytes are supposed to play several common roles in all tissues, and in 
addition, tissue specific functions in organs where they are particularly 
abundant. 
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Since both pericytes and VSC express some contracting molecules, such 
as Smooth-muscle actin (SMA), and exhibit a number of characteristics 
consistent with contractile activity, it is possible thet they are able to regulate 
blood flow. Moreover, pericytes are able to induce vasoconstriction and 
vasodilatation within capillary beds thanks to the their sensibility to endothelin-1 
(Rucker et al., 2000). 
Importantly, pericytes are involved in vessel stability. Through their long 
processes pericytes wrap the capillary and communicate with endothelial cells 
by direct physical contact and paracrine signals. Gap junctions provide direct 
connections between the cytoplasm of pericytes and endothelial cells and 
contain cell-adhesion molecules such as N-cadherin and beta-catenin and 
extra-cellular matrix (ECM) molecules such as fibronectin (Berger et al., 2005). 
Many pathways have been shown to take advantage from this particular 
connection. The loop signalling Tie2-Ang1, where Tie2 receptor is expressed on 
endothelial cells whereas its agonist ligand Ang1 is expressed mainly by 
perivascular and mural cells, has been shown to be essential for vessel 
maturation and stabilization (Sato et al., 1995; Suri et al., 1996). 
The process of skeletal muscle regeneration does not involve only muscle 
fibres, since also new vessels must be generated in order to repair damage 
tissue. Angiogenesis requires sprouting of endothelial cells (ECs) from pre-
existing vessels (Lamalice et al., 2007; Sun et al., 2005) and recruitment of 
perivascular cells (PVC), (Armulik et al., 2005; Armulik et al., 2011) particular 
cells that surround the endothelial vessels. 
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The origin of vascular smooth muscle cells is still not completely 
understood; there may be many different sources of perivascular progenitors. In 
general models, it is possible to find different recognize origin; from transi-
differentiation of other pericytes, from neural crest and also it seem that 
pericytes precursors are postulated to be recruited from local surrounding 
mesenchyme to the vascular wall by chemotactic factors secreted by 
endothelial cells, specifically endothelial tip cells. Tissue culture studies have 
shown that TGFβ1 cytokine promotes differentiation of mesenchymal 
precursors into PDGFRβ+ pericyte progenitors. During vessel growth, 
endothelial cells in the capillary plexus release PDGF-BB attracting in this way 
pericytes to the structure. PDGF pathway seems not to be essential for vessel 
development, but only for pericytes recruitment into the newly formed vessels, 
(Hellstrom et al., 1999) so mainly during vasculogenesis and angiogenesis. At 
the same time, TGF-β1 induces vessel maturation, inhibiting endothelial cell 
proliferation and migration (Orlidge and D'Amore, 1987; Sato et al., 1990).  
Recently by clonal analysis, it has been shown that at least a fraction of 
pericytes of the dorsal aorta derived from PAX3+/α-cardiac-actin+ precursors of 
hypaxial dermomyotome,(Esner et al., 2006) which has led to the suggestion of 
a somitic origin for a sub-set of perivascular cells. Moreover a novel common 
vascular precursor has been identified  (Flk1+ embryonic stem cells), that can 
give rise to EC by VEGF induction and to pericytes by PDGF-BB. According 
with this observation, it has been shown that ECs in chicken dorsal aorta can 
differentiate into VSMCs in developing vessels . 
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Fig 1.1.2 Pericytes origin 
Ectoderm-derived neural crest gives rise to vSMCs and pericytes in the CNS and thymus (light 
blue). Mural cells in coleomic organs are all mesoderm-and mesothelium-derived (violet). 
Epicardial mesothelium gives rise to mural cells in heart, lung mesothelium to pericytes in the 
lung, etc. Note that vSMC coverage around aorta has a multiple developmental origins, 
indicated by different colors (yellow, secondary heart field; light blue, neural crest; green, 
somite). 
 
In the adult, vascular smooth muscle cells can be generated from bone 
marrow derived cells or its stroma (Campbell et al., 2000). In addition fibroblasts 
can differentiate into myofibroblasts, which in turn differentiate into vascular 
SMCs in response to mechanical or biochemical cues (Sartore et al., 2001; 
Tomasek et al., 2002). Thus, the heterogeneity of pericytes is reflected in 
multiple developmental origins of these cells.  
 
suggests common lineages for vascular mural cells in any given
organ. The mentioned studies also point to close ontogenic rela-
tionships between mural cells and fibroblasts in many organs,
supporting current ideas of such relationships also in patholog-
ical situations (discussed below). In spite of a mesothelial origin
of pericytes in diverse organs such as heart, lung, liver, and gut,
the signaling mechanisms that govern their recruitment into their
final periendothelial location may be different. This is exemplified
by the importance of PDGF-B/PDGFRb signaling (further dis-
cussed below), which has been demonstrated in heart, lung,
and gut, whereas the development of hepatic stellate cells (liver
pericytes) occurs independently of PDGF-B/PDGFRb (H llstro¨m
et al., 1999). A similar distinction has beenmade for neural-crest-
derived pericytes, which depend on PDGF-B/PDGFRb signaling
in the CNS (Lindahl et al., 1997), but not in the thymus (Foster
et al., 2008).
Whereas some insights have thus been obtained into the
embryonic origin of pericytes in different organs, much less is
known about how pericytes grow and spread along growing
vessels in conjunction with developmental angiogenesis. Peri-
cytes proliferate during angiogenesis in the CNS and in vitro,
and the seeming lack of immature mesenchyme in the devel-
oping CNS would imply that new pericytes develop mainly by
proliferation of pre-existing ones in this organ. However, to
what extent new pericytes develop by division of pre-existing
pericytes—by recruitment (proliferation, migration, and differen-
tiation) from pre-existing vSMCs on neighboring large vessels
and/or by differentiation from immature mesenchyme, or
both—in most other organs are issues that are presently not
definitively resolved. The same holds true for the question about
ontogenetic relationships between pericytes and vSMCs. The
continuum of mural cell phenotypes observed along terminal
arterioles, capillaries, and postcapillary venules might suggest
that these cells can differentiate into each other in conjunction
with vessel growth and remodeling, but this also requires further
inve tigation.
Signaling Pathways Implicated in the Development of
Pericytes and Their Interaction with Endothelial Cells
As discussed above, the anatomical relationship between peri-
cytes and endothelial cells suggests close interactions involving
paracrine or juxtacrine signaling (Figure 4). Endothelial-pericyte
signaling has recently been reviewed in detail (Gaengel et al.,
2009). Below we cover briefly this area and point out recent
advances in the understanding of how different intercellular sig-
naling pathways play a role in vascular development and
stability.
PDGF-B/PDGFRb
PDGF-B is released from angiogenic endothelial cells and binds
to PDGFRb expressed on the surface of developing pericytes. As
NEURAL CREST
MESOTHELIUM
AORTA
Figure 3. Developmental Origin of Mural Cells
Ectoderm-derived neural crest gives rise to vSMCs and pericytes in the CNS
and thymus (light blue). Mural cells in coleomic organs are all mesoderm- and
mesothelium-derived (violet). Epicardial mesothelium gives rise to mural cells
in heart, lung mesothelium to pericytes in the lung, etc. Note that vSMC
coverag around aorta has a multiple developmental origins, indicated by
different colors (yellow, secondary heart field; light blue, neural crest; green,
somite).
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Figure 4. Signaling Pathways Mediating Mural Cell Recruitment,
Differentiation, and Vascular Stabilization
Pericyte recruitment to the endothelium is mediated by multiple ligand-
receptor complexes: PDGF-B/PDGFRb, SDF-1a/CXC4R, HB-EGF/ErbB,
Shh/Ptc, and Ang1/Tie-2. The cellular response to TGFb/TGFbR signaling axis
is dependent on the composition of the receptor and the relative level of the
ligand. A ligand-receptor pair is indicated by the same color. N-cadherin and
Notch-mediated vessel stabilization requires direct contact between a peri-
cyte and an endothelial cell. Note that some signaling pathways are currently
only proposed to be relevant for pathological angiogenesis (see text for
details).
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Figure 1.1.3 Pericytes localization 
(A) A continuum of mural cell cyto-architecture from arteriole to venule. A single vSMC layer 
around arterioles and precapillary arterioles encircles the entire abluminal side of the 
endothelium. vSMCs around arterioles have a flattened, spindle-shaped appearance with few 
cytoplasmic processes, whereas around precapillary arterioles the cell bodies are distinctly 
protruding and extend several processes encircling the endothelium. Pericytes investing 
capillaries have a nearly rounded cell body that gives rise to a few primary processes running 
on the endothelium in the length of the capillary. The primary processes give rise to secondary 
perpendicular processes. The tips of secondary processes attach firmly to the endothelium.  
(B) Ultrastructural characteristics of pericytes and pericyte-endothelial interactions. Pericytes 
are rather anonymous in transmission electron microscopy. The mature capillary pericyte (P) 
has a discoid nucleus that is surrounded by a small amount of cytoplasm containing protein-
producing organelles and mitochondria. Despite being separated by the shared BM, pericytes 
and endothelial cells (E) make numerous direct contacts of different type: schematically 
depicted are peg-socket contacts and adhesion plaques. Adapted from (Armulik et al., 2011) 
 
Pericytes extend primary cytoplasmic processes along the ablu-
minal surface of the endothelial tube. These proc sses usually
span several endothelial cells and occasionally bridge neigh-
boring capillary branches. At capillary branch points, which
commonly harbor a pericyte soma, primary processes are often
found to extend along each branch, conferring a cellular
Y-shape. Thin secondary processes extend from the primary
processes. These are usually perpendicular in their orientation
relative to the primary branches, thereby partially encircling the
vessel (Fig e 1A).
Ultrastructure
The pericytes are enveloped in a BM that is continuous with the
endothelial BM. Pericytes probably contribute products to the
BM, and in vitro analysis demonstrates that pericyte-endothelial
interactio regulates BM assembly (Stratma et al., 2009, 2010).
Mature pericytes thus become embedded within a capillary
BM, a feature that makes it possible to identify primary and
secondary pericyte processes by transmission electrommicros-
copy in ultrathin sections (Sims, 1986). It is unclear to what extent
mature pericytes are always fully BM embedded. The literature
contains many descriptions of incomplete or even absent BM
coverage (reviewed by Dı´az-Flores et al., 2009). The relationship
between the pericyte and the microvascular BM is hard to see in
embryonic tissue or in pathological situations, where angiogen-
esis is active and the BM in a state of synthesis or turnover.
Here, the distinction between pericytes and other perivascular
mesenchymal cells is particularly problematic.
The majority of the pericyte-endothelial interface is separated
by a BM (Figure 1B). However, at discrete points, the two cell
types contact each other at holes in the BM. The number and
size of pericyte-endothelial contacts may vary between tissues,
but up to 1,000 contacts have been described for a single endo-
thelial cell. The contacts are of peg-socket type, in which peri-
cyte cytoplasmic fingers (pegs) are inserted into endothelial in-
vaginations (pockets). Other contact morphologies have been
described, including sites where the two membranes come
v ry close together (close or occluding contacts). These are
located at the edge of the pericyte processes and possibly
play an anchoring role. Another type of contacts, referred to as
adhesion plaques, show microfilament bundles attached at the
pericyte plasma membrane and electron-dense material in the
opposing endothelial cytoplasm. They contain fibronectin and
resemble adherence junctions ultrastucturally. Possibly, these
are the sites where N-cadherin-based connections are formed
between ndothelial cells and pericytes (Gerhardt and Betsholtz,
2003; Gerhardt et al., 2000). Gap junction-like structures have
also been reported at contacts between endothelial cells and
pericytes (Dı´az-Flores et al., 2009). These observations are
somewhat anecdotal, however, and functional evidence for
gap junctions between endothelial cells and pericytes exists
in vitro (Larson et al., 1987), but not in vivo. As discussed below,
the production of TGFb by endothelial and mural cells may
require their contact through gap junctions.
Pericyte Abundance
The pericyte density varies between different organs and
vascular beds, and the proportion of the endothelial abluminal
surface that is pericyte covered varies as well. The central ner-
vous system (CNS) vasculature is generally regarded as being
the most pericyte covered, with a 1:1–3:1 ratio between endo-
thelial cells and pericytes, and an approximately 30% coverage
of the abluminal surface (Mathiisen et al., 2010; Sims, 1986).
Significantly lower ratios have been reported for some other
tissues, e.g., human skeletal muscle, which has been stated to
have a 100:1 endothelial-to-pericyte ratio (reviewed in Dı´az-
Flores et al., 2009; Shepro and Morel, 1993). Although there is
undoubtedly variation, very low figures like this one are based
on singular reports and may be questioned since much higher
ratios have been described in skeletal muscle in other studies
(Tilton et al., 1979). If true, it would also imply that many endothe-
lial cells would be without pericyte contact, a situation that has
arteriole
capillary
venule
A B
peg-socket
adhesion plaques
caveolae
basement membrane
P
Epostcapillary venule
precapillary arteriole
Figure 1. Pericyte Anatomy
(A) A continuum of mural cell cyto-architecture from
arteriole to venule. A single vSMC layer around
arterioles and precapillary arterioles encircles the
entire abluminal side of the endothelium. vSMCs
around arterioles have a flattened, spindle-shaped
appearance with few cytoplasmic processes,
whereas around precapillary arterioles the cell
bodies are distinctly protruding and extend several
processes encircling the endothelium. Pericytes
investing capillaries have a nearly rounded cell body
that gives rise to a few primary processes running
on the endothelium in the length of the capillary. The
primary processes give rise to secondary perpen-
dicular processes. The tips of secondary processes
attach firmly to the endothelium. On postcapillary
venules themural cell body flattens and gives rise to
many slender, branching processes. vSMCs cov-
ering venules have a relatively big, stellate shape
cell body with many branching processes, which,
unlike arteriolar vSMCs, do not wrap circularly
around the endothelium.
(B) Ultrastructural characteristics of pericytes and pericyte-endothelial interactions. Pericytes are rather anonymous in transmission electron microscopy. The
mature capillary pericyte (P) has a discoid nucleus that is surrounded by a small amount of cytoplasm containing protein-producing organelles andmitochondria.
Microtubules str tch along the primary and secondary cytoplasmic extensions. Intermediate filaments composed of desmin and vimentin are mostly
concentrated within in the primary extensions. Dense bands of microfilaments containing actin, myosin, and tropomyosin are concentrated beneath the plasma
membrane, in particular the inner surface m mbrane fac ng the endothelium. Th outer, abluminal pericyte surface often shows numerous caveolae. Despite
being separated by the shared BM, pericytes and endothelial cells (E) make numerous direct contacts of different type: schematically depicted are peg-socket
contacts and dhesion plaques.
194 Developmental Cell 21, August 16, 2011 ª2011 Elsevier Inc.
Developmental Cell
Review
 18	  
1.1.3 Pericyte Plasticity  
Recent new experiments suggested that pericytes have the ability to 
differentiate into different cells of mesodermal lineages. 
Canfield and colleagues have shown that pericytes of bovine retina are 
able to differentiate into osteoblasts, chondrocytes and adipocytes in vitro and 
in vivo. In these experiments pericytes were inoculated into diffuse chambers 
that has been implanted into athymic mice; after a few months the tissue 
contained areas resembling bone (von Tell et al., 2006)or mineralized cartilage 
with lacunae containing chondrocytes. Moreover cells resembling adipocytes 
could also be detected. In vitro studies confirmed this plasticity(von Tell et al., 
2006).  
The pericytes’s ability to differentiate into osteoblasts and bone opened 
the possibility that these phenomena may be implicated in ectopic calcifications 
that can be detected in arteries of the heart and skeletal muscle . Recently, it 
has been hypothesised that the skeletal muscle ossification detectable in 
Fibrodysplasia ossificans progessiva (FOP) may have a vascular origin, and in 
particular that it can be due to anomalies in the normal pericyte pathway that 
leads to increase the osteoblastic differentiation (Hegyi et al., 2003). 
Another suggestion of pericyte plasticity comes from studies in which 
Annexin 5 was used to isolate a novel perivascular population that resembles 
mesenchymal stem cells. Anx5-lacZ+ cells isolated from embryonic brain 
meninges, by FACS sorting, express several stem cell markers such as Flk1, c-
kit, Sca-1, and can differentiate into an adipogenic, chondrogenic and 
osteogenic phenotype in vitro. (Brachvogel et al., 2005) 
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1.1.4 Akaline phosphatase 
Alkaline phosphatases (AP; ortophosphomonoester phosphoidrolase) are 
a group of membrane-bound glycoproteins that hydrolyze a large range of 
monophosphate esters at alkaline PH optima.  
In human 4 isoforms of AP are know, the placental (PL-AP) the testicular 
germ-cell (GC-AP); the intestinal (I-AP) and the tissue aspecific AP (mainly 
present in bone-liver-kidney, TN-AP). I-AP, CG-AP and PL-AP show a very high 
homology: a minimum of 90% sequence identity at amino acid level, all map on 
chromosome number 2; (Martin et al., 1987) whereas TN-AP is only 57% 
identical to I-AP at the aminoacid level. It maps to a distal short arm of 
chromosome number 1 (Smith et al., 1988) and it is constituted of 12 exons 
distributed over more that 50 Kb . 
In mouse only three isoforms have been identified: the placental AP (PL-
AP) and the intestinal AP (I-AP) that are homolog and map on chromosome 
number 1 and the tissue non-specific AP (TN-AP) on chromosome number 4. 
The mouse TN-AP gene is constituted of 12 exons, as the human counterpart, 
and the ATG is localized on exon number 2. (www.ensembl.org)  
 Physiological function of alkaline phosphatase in still unknown; by 
histochemical staining it appears at the late 2-4 cell stage in the mouse embryo 
(Mulnard and Puissant, 1987) (Mulnard J, 1987). The only information about AP 
gene regulation has been detected in bone where TN-AP levels of expression 
increase markedly when mineralization is actively occurring (Register and 
Wuthier, 1984). In in vitro assays AP expression is used as indicator of 
osteoblastic differentiation (Minasi et al., 2002). 
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Even if TN-AP expression is very strong in tissues as kidney, bone and 
liver, it is actually diffusely expressed in many tissues of the body. The first 
evidence of TN-AP expression on capillaries was detected in 1965; (Mizutani 
and Barrnett, 1965) other studies later on have shown its presence in capillaries 
and pericytes of rat, mice and guinea pig myocardium. (Schultz-Hector, 1993) 
Most importantly, AP has been shown to be expressed in intramuscular 
connective tissue and in capillary-ends of striated muscle in many animal types 
(such as chick, quail, mouse, rabbit, hamster, guinea pig, dog, monkey) and 
human. (Grim and Carlson, 1990; Safadi et al., 1991) The AP positive cells can 
be easily isolated from adult skeletal muscle and cultured in vitro, they present 
a mesenchymal morphology and maintain AP expression along with other 
typical pericyte markers.(Levy et al., 2001; Lindner et al., 1997) 
Moreover recent work demonstrated that resident pericytes in skeletal 
muscle isolated through AP expression, contributes to muscle growth and to are 
able to enter the satellite cell compartment during postnatal 
development.(Dellavalle et al., 2011)  
1.2. Myogenesis 
1.2.1 The Onset of Myogenesis 
 
 PAX family consists of nine transcription factors, which have common 
paired, homeodomain and octapeptide domains. Each member of this family 
has a crucial role in organogenesis during embryonic and fetal development. 
(Chalepakis et al., 1992) PAX proteins regulate a wide variety of cellular 
processes, including cell proliferation, self-renewal, apoptosis, migration and 
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differentiation. (Chalepakis et al., 1992)They are further divided into four 
subfamilies based on their structural and expression domains.(Gruss and 
Walther, 1992) The Pax3/7 subfamily regulates both myogenesis (Buckingham 
and Relaix, 2007) and neurogenesis in the neural crest (Koblar et al., 1999). 
Pax3 is first expressed in the presomitic mesoderm (Williams and Ordahl, 
1994)and is required for survival of the ventro-lateral dermomyotome, which 
gives rise to the hypaxial and limb musculature. (Teboul et al., 2002) Pax7 is 
expressed later, in the central dermomyotome, (Jostes et al., 1990) and is 
thought to be essential only during postnatal myogenesis (Seale et al., 2000). A 
cell population has been identified that expresses both Pax3 and Pax7, but no 
additional markers of skeletal muscle such as MyoD or desmin; (Kassar-
Duchossoy et al., 2004; Relaix et al., 2006) these cells proliferate in embryonic 
and fetal muscles of the trunk and limbs throughout development. (Relaix et al., 
2006) In the absence of both Pax3 and Pax7, muscle development is arrested 
and precursor cells do not leave the myotome. (Lagha et al., 2005)However, 
Pax3 and Pax7 exhibit divergent functions in development: Pax7 can substitute 
for Pax3 in dorsal neural tube, neural crest cell, somite and muscle formation in 
the trunk, but not in muscle formation in the limbs.(Relaix et al., 2004) At the 
same time, Pax3 cannot substitute for Pax7 in postnatal skeletal muscle.(Lagha 
et al., 2008) Deletion of Pax3 leads to death of progenitor cells in the hypaxial 
somite, (Buckingham and Relaix, 2007) and Pax3 also is required for the 
delamination and migration of muscle progenitor cells to sites where skeletal 
muscle will form, such as the limbs. (Franz et al., 1993)Ectopic Pax3 can drive 
myogenesis of embryonic carcinoma (Darabi et al., 2008; Franz et al., 1993) 
cells and embryonic stem cells. In the adult, Pax3 is expressed in a variety of 
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muscles, but to differing degrees in different muscles. (Teboul et al., 
2002)These observations collectively raise important questions about the 
potential developmental and anatomic diversity of the functions of Pax3. 
Similarly to Pax proteins, the four canonical myogenic regulatory factors 
(MRFs) Myf5, MyoD, myogenin and Mrf4 have also been intensively studied in 
early development. All these MRFs were initially characterized by virtue of their 
ability to convert certain non-muscle cell lines, such as fibroblasts, into 
myoblasts and myotubes. (Weintraub et al., 1991) Studies in targeted mice 
revealed that the MRFs are essential, to differing extents, for prenatal skeletal 
muscle development (Weintraub et al., 1991) but are in large part redundant so 
that a single null allele has a mild phenotype. Pax3 can directly transactivate 
Myf5 and myogenin expression during embryonic myogenesis, (Bajard et al., 
2006)and Pax3 also appears to activate MyoD in some circumstances, (Maroto 
et al., 1997; Tajbakhsh et al., 1997) although this regulation is probably indirect. 
(Buckingham and Relaix, 2007) In contrast to developing muscle, Pax3 does 
not transactivate Myf5 in the adult. (Relaix et al., 2006) 
It is widely accepted that all the skeletal muscles in vertebrate body, with 
the exception of some craniofacial muscles (see below), derive from progenitors 
present in the somites.  
Somites are transient mesodermal units, which form in a cranio-caudal 
succession by segmentation of the paraxial mesoderm on both sides of the 
neural tube. Each newly formed somite rapidly differentiates into a ventral 
sclerotome and a dorsal dermomyotome from which myogenic precursors 
originate. Shortly after the onset of somitogenesis (at E 8.75 in the mouse) 
myogenic progenitor cells differentiate into the differentiated, mononucleated 
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muscle cells (myocytes) of the “primary” myotome. Primary myotome formation 
is a multistep process in which precursors translocate from the dermomyotome 
to a ventrally located domain where they elongate along the axis of the embryo 
to span the entire somite length. This process has been intensively studied and 
some aspects are still subject of controversy. (Hollway and Currie, 2005; 
Kalcheim and Ben-Yair, 2005; Venters et al., 1999)Nevertheless the final 
pattern is relatively simple, with all muscle cells aligned along the whole cranio-
caudal length of the somite, likely as a remnant of muscle differentiation in fish. 
The role that the myotome exerts during development of higher vertebrates 
remains unclear. It has been proposed that myotomal cells can act as a kind of 
scaffold for successive waves of myoblasts. Nevertheless in the Myf5 null mice, 
where a primary myotome fails to form, myogenesis proceeds in a relatively 
normal sequence (Braun et al., 1992; Tajbakhsh et al., 1996)suggesting that 
formation of the primary myotome is not a necessary step for later muscle 
development in amniotes. 
Only a minor fraction of myogenic progenitors terminally differentiate 
during primary myotome formation. As schematized in figure 1.2.1, skeletal 
muscle is established in successive distinct, though overlapping steps involving 
different type of myoblasts (embryonic, foetal myoblasts and satellite cells). The 
continued growth of muscles that occurs during late embryonic (E10.5-12.5), 
foetal and post-natal life was recently attributed to a population of muscle 
progenitors that arise in the central part of the dermomyotome (Ben-Yair and 
Kalcheim, 2005; Kassar-Duchossoy et al., 2004; Relaix et al., 2005; Schienda 
et al., 2006) 
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Around 90% of these skeletal muscle progenitor cells co-express Pax3 
and Pax7 until E14.5. These progenitors can differentiate into skeletal muscle 
fibres during embryogenesis or remain as a reserve cell population within the 
growing muscle mass during peri and postnatal stages. In Pax3\Pax7 double 
mutant the generation of primary myotome is unaffected, whereas successive 
phases of myogenesis are compromised, due to the non myogenic fate adopted 
by these progenitors. Therefore it has been proposed that all the cells of the 
myogenic lineage (with the exception of myotomal cells) could derive from 
Pax3/7 positive population of myogenic progenitors resident in the central part 
of the dermomyotome.  
At around day E 11.5 (in the mouse), during a phase, which is usually 
referred as primary myogenesis, embryonic myoblasts invade the myotome and 
fuse into myotubes, likely incorporating the initially mononucleated myocytes of 
the myotome, even though this has not been formally demonstrated. These are 
the first multinucleated muscle fibres, that appear in the embryo and are known 
as primary fibres. (Dunglison et al., 1999; Evans et al., 1994; Zhang and 
McLennan, 1995) A new wave of myogenesis takes place between 14.5 and 
17.5 d.p.c. This phase is called secondary myogenesis and depends upon 
fusion of foetal myoblasts that give rise to secondary fibres (originally smaller 
and surrounding primary fibres with a donut like configuration) but also fuse with 
primary fibres. At the same time a basal lamina begins to form around each 
fibre and it is only after its formation that satellite cells can be morphologically 
and different types of mesodermal stem cells (i.e mesoangioblasts) have the 
potential to participate to muscle regeneration, though their contribution appear 
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to be minimal under normal circumstance. (Cossu and Biressi, 2005; Ferrari 
and Mavilio, 2002) 
Old work from our and other laboratories identified specific features of 
embryonic, foetal myoblasts and satellite cells that characterize them as distinct 
classes of myogenic cells. (Cossu and Biressi, 2005; Cossu and Molinaro, 
1987; Miller et al., 1999; Zappelli et al., 1996)Embryonic and foetal myoblasts, 
presumed to generate primary and secondary fibres respectively, differ for the 
morphology of the myotubes they generate where different myosin heavy 
chains isoforms and muscle enzymes are expressed. (Barbieri et al., 1990; 
Bonner and Hauschka, 1974; Ferrari et al., 1997; Pin and Merrifield, 1993)They 
also differ for media requirements (White NK, 1975), integrin-extracellular 
matrix interactions, (Blanco-Bose et al., 2001) resistance to inhibitors of 
myogenesis such as phorbol esters  and TGFβ.(Zammit and Beauchamp, 2001) 
Specific features have been reported also for satellite cells: i.e morphology, 
susceptibility to TGFb but resistance to phorbol esters induced block of 
differentiation, high PDGF binding capacity, (Yablonka-Reuveni and Seifert, 
1993) early expression of acetylcholine receptors (Cossu G, 1987) and acetyl-
cholinesterase, (Senni et al., 1987) high clonogenic capacity, differential ability 
to respond to topographical guidance cues  and expression of muscle specific 
genes (Hartley RS, 1991). 
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Figure 1.2.1 Proposed lineage sheme for skeletal muscle.   
The somatic dermomyotome is the origin of the myotomal cells, which differentiate into the 
myocytes of early myotome (first terminally differentiated muscle of the embryo). Pax3/Pax7 
positive cells identified in the dermomyotome release muscle precursor during development 
(embryonic fetal myoblast and satellite cells). Embryonic and fetal myoblast give rise to 1° and 
2° fibres respectively. Satellite cells appear at the end of the gestation and are responsible of 
post natal growth and regeneration. 
Abbreviations used: d.p.c days post coitum; HSC haematopoietic stem cells; MSC mesodermal 
stem cells 
1.2.2 Asynchronous differentiation during muscle development 
Embryonic myogenesis begins in newly formed somites where dorsally 
located progenitors respond to signals such as Wnts and Shh, emanating from 
adjacent neural tube, notochord and ectoderm, and activate basic Helix loop 
Helix transcription factors (Myf5 and MyoD) that commit cells to myogenesis 
rise to terminally differentiated, mononucleated muscle cells
(myocytes) of the primary myotome. Primary myotome form-
ation is a multistep process in which precursors translocate from
the dermomyotome to a ventrally located domain where they
elongate along the axis of the embryo to span the entire somite
length. This process has been intensively studied, especially in
the avian embryo, but some aspects remain controversial
(Cinnamon et al., 1999, 2001; Denetclaw and Ordahl, 2000;
Denetclaw et al., 1997, 2001; Gros et al., 2004; Kahane et al.,
1998, 2001, 2002; Kahane and Kalcheim, 1998; Ordahl et al.,
2001; Venters and Ordahl, 2002). Nevertheless the final pattern
is relatively simple, with all muscle cells aligned along the
whole cranio-caudal length of the somite. The role of the myo-
tome during development of higher vertebrates remains unclear.
However in Myf5nlacZ/nlacZ mice, in which the expression of
both Myf5 and MRF4 is abolished and that fail to form a
primary myotome, myogenesis proceeds in a relatively normal
sequence (Tajbakhsh et al., 1996) suggesting that formation of
the primary myotome is not essential for later muscle deve-
lopment in amniotes or that, alternatively, the later development
of a MyoD dependent similar structure is sufficient to drive an
almost normal muscle development.
Only a fraction of myogenic progenitors terminally differ-
entiate during primary myotome formation. As schematized in
Fig. 1, skeletal muscle is established in successive distinct,
though overlapping steps involving different type of myoblasts
(embryonic, fetal myoblasts and satellite cells). The continued
growth of muscles that occurs during late embryonic (E10.5–
12.5), fetal (E14.5–17.5) and postnatal life was recently
attributed to a population of muscle progenitors already present
at embryonic stage (Gros et al., 2005; Kassar-Duchossoy et al.,
2005; Relaix et al., 2005; Schienda et al., 2006). These skeletal
muscle progenitor cells arise in the central part of the dermo-
myotome, co-express Pax3 and Pax7 and can differentiate into
skeletal muscle fibers during embryogenesis or possibly remain
as a reserve cell population within the growing muscle mass
during peri- and postnatal stages. In Pax3/Pax7 double knock-
out mice generation of the primary myotome is unaffected,
whereas successive phases of myogenesis are compromised due
to the non-myogenic fate adopted by these progenitors. It has
therefore been proposed that all of the cells of the myogenic
lineage (with the exception of myotomal cells) may be derived
from a Pax3/Pax7 positive population of myogenic progenitors
resident in the central part of the dermomyotome.
At around E11 in the mouse, embryonic myoblasts invade
the myotome and fuse into myotubes, probably incorporating
the initially mononucleated myocytes of the early myotome,
although this has not been formally demonstrated. Grossly at the
same stage, during a phase which is usually referred as primary
myogenesis, myogenic progenitors, which have migrated from
the dermomyotome to the limb, start to differentiate into multi-
nucleated muscle fibers, known as primary fibers. This embryo-
nic phase appears to depend upon MRF4 since it is maintained
in the Myf5 null embryo but is disrupted in the Myf5-MRF4
double mutant embryo (Kassar-Duchossoy et al., 2004). A new
wave of myogenesis takes place between E14.5 and E17.5. This
phase is called secondary myogenesis and involves fusion of
fetal myoblasts either with each other to give rise to secondary
fibers (originally smaller and surrounding primary fibers) (Dux-
son et al., 1989) and also with primary fibers (Dunglison et al.,
1999; Evans et al., 1994). It is only at the end of this phase that
satellite cells can be morphologically identified as mononu-
cleated cells lying between the basal lamina and the fiber plas-
ma membrane. During peri- and postnatal development, satellite
cells divide at a slow rate and a large part of the progeny fuse
with the adjacent fiber to contribute new nuclei to growing
muscle fibers (whose nuclei cannot divide), so that the majority
of the nuclei of a mature muscle are presumably derived from
Fig. 1. Proposed lineage scheme for skeletal muscle. The somitic dermomyotome is the origin of the myotomal cells, which differentiate into the myocytes of the early
myotome. Pax3/Pax7 positive cells identified in the dermomyotome release muscle precursors during development (embryonic, fetal myoblasts and satellite cells).
Embryonic and fetal myoblasts give rise to 1° and 2° fibers, respectively. Satellite cells appear at the end of gestation and are responsible for postnatal growth and
regeneration. Other non-somitic progenitors are involved in muscle regeneration, although their role in non-pathological conditions remains largely unexplored.
Abbreviations used: d.p.c. days post coitum. An indicative timing of murine development is depicted.
282 S. Biressi et al. / Developmental Biology 308 (2007) 281–293
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(for a more detailed description of embryonic myogenesis, several reviews can 
be consulted.(Cossu and Borello, 1999; Cossu et al., 2000; Pownall et al., 
2002) Nevertheless the observation that only a fraction of myogenic progenitors 
present in the dermomyotome terminally differentiate during somitogenesis and 
that other myogenic cells differentiate in successive phases, suggest that cells 
situated in the same environment should understand the same signals in a 
different way. The Pax3/Pax7 muscle-progenitor cells may represent a mixed 
population of cells with different developmental potential. Even assuming that 
all canonical myogenic cells (embryonic and foetal myoblasts and satellite cells) 
may be specified to myogenesis in the newly formed somite, most of these cells 
should be kept in a committed but undifferentiated state until subsequent 
phases of myogenesis. In Drosophila lateral inhibition through Notch and Delta 
has been shown as the probable mechanism by which adult myogenic 
progenitors are selected in response to Wnt signalling. (Baylies et al., 1998) 
Recently a similar mechanism has been shown to operate in adult muscle. 
(Conboy and Rando, 2002) Thus it appears likely that the same may occur in 
the mammalian somite. Indeed several Delta and Notch isoforms are expressed 
in the somites (McGrew and Pourquie, 1998) and Notch inhibits myogenesis, 
probably through different intra-cellular mechanisms. (Nofziger et al., 1999; 
Wilson-Rawls et al., 1999) Receptors for growth factors or other signalling 
molecules such as BMP or TGFβ may be pertinent targets for Notch signalling. 
However direct evidence for a role of Notch in diversifying cell fate in 
mammalian somites is still missing. Here in fact we report data that support a 
possible explanation; in fact it’s already know that Notch act as a determinant 
between smooth and skeletal muscle, but now can think that Notch could also 
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reprogram an already committed cells .A possible mechanism to ensure that 
certain myoblasts/progenitors will differentiate in an environment that is 
permissive for proliferation may be based on the inability of these cells to 
respond to growth factors and/or to molecules, which inhibit differentiation. 
Some years ago, a possible mechanism was proposed by which TGFβ might 
influence the process of primary fibres formation in vivo, by inhibiting 
differentiation of fetal myoblasts and satellite cells but not of embryonic 
myoblasts. At late foetal stage intensive foetal myoblast fusion still occurs, 
leading to a drastic reduction of myogenic mononucleated cells. Since satellite 
cells do not undergo differentiation at this time, the control of proliferation and 
differentiation in these cells must be still different, so as to allow the persistence 
of mononucleated undifferentiated myogenic cells in the post-natal and in the 
adult muscle. Thus to the generation of the different phases of myogenesis 
appears to be finely regulated. Nevertheless the molecular mechanisms 
operating in these cells remain unexplained. 
1.3 Fiber diversity in skeletal muscle 
1.3.1 Primary and secondary fibres 
All fibres are produced by the fusion of myogenic cells, but muscle fibre 
formation in vertebrates is multiphasic. Both in avian and in rodents, where the 
process has been studied in detail, an early and a late wave of fibre production 
can be recognised. During the early phase, fibres, usually referred as primary 
(or embryonic) fibres, are generated by the fusion of early appearing 
(embryonic) myoblasts. During primary myogenesis muscles consists of a small 
numbers of myotubes. Primary myotubes progressively increase in size 
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becoming larger and with a characteristic round shape in transverse sections. 
Later-forming fibres are called secondary (or foetal) fibres and are likely 
generated by the fusion of the late appearing foetal myoblasts. During this 
process, referred as secondary myogenesis, secondary fibres form on the 
surface of primary fibres to which they remain attached for a short period. The 
secondary myotubes subsequently elongate and become independent fibres, 
which can be distinguished from primary fibres by their relative small size. The 
innervation of muscles starts while fibres are still forming. Each muscle fibre is 
initially innervated by multiple axons, all but one of which are subsequently 
eliminated. After birth, all the muscle fibres that remain contacted by the axon 
branches of an individual motor neuron are of the same type. The detailed 
mechanisms whereby nerves become associated with fast or slow muscle 
fibres are currently unknown, but it is currently assumed that that nerves play a 
role in generating fibre type diversity while different muscle fibres are 
predisposed to receive the appropriate axons. Skeletal muscle development is 
influenced by innervation, in the absence of which primary and secondary fibers 
still form almost normally but later do not grow in size and eventually some 
degenerate leading to a reduction of the total number of fibres. Continued 
denervation leads to eventual degeneration of both primary and secondary 
fibres.(Evans et al., 1994) As mentioned before for embryonic and foetal 
myotubes generated in vitro, also primary and secondary fibres differ in the 
expression of myosin heavy chains (MyHC) isoforms. In mammals primary 
fibres express embryonic (fast) and I/β(slow)-MyHC and only shortly before the 
end of primary fibre formation some of them (generally located on the 
superficial edge of the muscles) express also the perinatal/neonatal (fast) 
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isoform. On the contrary secondary fibres express all (fast) embryonic and 
perinatal isoforms from their inception and (with the exception of the soleus 
muscle) don’t express I/β (slow)-MyHC. Thus it can be generalized, that in  
mammals primary fibres (and embryonic myoblasts) are programmed to 
express predominantly a slow phenotype, whereas secondary fibres (and foetal 
myoblasts) more a fast phenotype. (Wigmore and Evans, 2002) Beside myosin 
isoforms, a few other genes, such as Muscle creatine kinase,(Ferrari et al., 
1997) β-Enolase (Feo et al., 1990) and PCθ (Zappelli et al., 1996) have been 
reported to be differentially expressed between primary and secondary fibres. 
Moreover alteration of genes which specifically affect primary or secondary 
myogenesis have been also identified (Cachaco et al., 2003; Fazeli et al., 1996; 
Kegley et al., 2001)further confirming the different nature of primary and 
secondary fibres in vivo. 
 
1.3.2 Relationship between developing and mature phenotypes  
Embryonic and fetal myoblasts have an intrinsic ability to form fibres 
expressing different MyHC isoforms, which broadly reflect the isoforms initially 
formed by primary and secondary fibres. After birth the total number of fibers in 
a given muscle of a given species remains constant but the total number of 
nuclei in each fibre increases up to ten folds: most nuclei in mature fibre are 
derived from satellite cells. It is still unclear whether the characteristics of an 
adult fibre reflect the features of the numerically dominant satellite cell nuclei or 
if the myoblasts which first form a fibre may continue to profoundly influence the 
proprieties of the fibre also when hundreds of satellite cells has been 
incorporated. The “slow” phenotype of primary fibres and the “fast” phenotype 
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of secondary fibres suggest a correlation respectively with the adult slow and 
fast contracting fibres. It should be noted that few new nuclei are added at any 
given time and thus represent a minority of the total nuclei in a fibre. Thus it 
may be possible that signals emanating from resident nuclei reprogram the 
newly added ones. Alternatively the different proprieties of an adult fibre could 
depend on heterogeneity in the satellite cell population. Some evidence 
supported this hypothesis. Nevertheless satellite cells do not show a 
predisposition to fuse with a particular fibre type in vivo suggesting that the 
different characteristics of the fibres may not simply derive from intrinsic 
proprieties of satellite cells. Environmental influences (activity, hormones etc.) 
could also have an important role in the establishment of fibre type diversity as 
mentioned above. It is conceivable that similar extrinsic signals could act also 
during fibre generation. Individual fibres have a characteristic proportion and 
distribution of fibre types, with fast fibres tending to be more superficial than 
slow fibres. This suggests that the distribution of fibre types is controlled by 
signals coming from adjacent tissues. Diffusible molecules such as Shh 
(Blagden et al., 1997)or member of the Wnt gene family, which have been 
shown to be involved in the initiation of myogenesis in the somites, could be 
involved. (Cossu and Borello, 1999; Wigmore and Evans, 2002)Moreover motor 
innervation appears to play an important instructive role in determining fibre 
type specification. Muscle cells from fetal slow muscle express slow myosin 
only when co-cultured with neural tube, whereas muscle cells from fetal fast 
muscle do not express slow myosin even in presence of neural tube, 
suggesting that the expression of MyHC isoforms during development is 
probably regulated by both myoblast lineage and innervation.(DiMario and 
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Stockdale, 1997) In conclusion it is reasonable that the mature characteristics 
of a fibre could be determined in part by extrinsic and in part by intrinsic factors, 
although is difficult to ascertain which of the two exert the major role. Even less 
clear is the degree of influence that the founding nuclei (from embryonic or 
foetal myoblasts) exhert on the numerically dominant, later incorporated nuclei 
(from satellite cells) in regulating the adult fibre phenotype.  
 
1.4 Anatomical heterogeneity in skeletal muscle 
1.4.1 Epaxial and Hypaxial myogenesis 
A complex array of muscles is present in the vertebrate body. Based on 
their innervation pattern it is possible to distinguish the epaxial muscles, 
innervated by the dorsal branch of the spinal nerves, and the hypaxial 
innervated by the ventral branch. Epaxial muscles are located dorsally and 
correspond to the deep muscles of the back in amniotes, whereas hypaxial 
muscles are located superficially, laterally and ventrally and include diaphragm, 
body wall and limb muscles. The two type of muscles are physically separated 
by a connective tissue sheet. In amniotes all the trunk muscles derive from the 
somitic dermomyotome. During this process, myogenic progenitors derived 
from the dermomyotome create in successive phases (see above), in the area 
between the dermomyotome and the medio-ventrally located sclerotome, a 
structure called myotome or alternatively undergo a ventral migration towards 
sites of hypaxial myogenesis such as the limb or the tongue.  
Each dermomyotome (and myotome) can be subdivided into a hypaxial 
(underneath the axis-notochord) and an epaxial portion. The former is located 
more ventro-laterally and give rise to hypaxial muscles, whereas the latter is 
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located dorso-ventrally and will origin the epaxial muscles. (Cossu et al., 2000) 
Work of several laboratories showed that only the precursors of the epaxial are 
dependent upon signal from axial structures, whereas precursors of the 
hypaxial muscles do not need neural tube and notochord for the myogenic 
commitment but rather signals from the dorsal ectoderm (Fig. 2.4.1). In 
particular it was shown that axial structures, probably trough the release of Shh 
and Wnts (i.e. Wnt1) preferentially activate a myogenic program by inducing 
Myf5 expression. On the contrary dorsal ectoderm, by releasing different 
members of the Wnt family (i.e. Wnt7a), activate the myogenic program through 
a MyoD mediated pathway. (Cossu and Borello, 1999; Cossu et al., 2000) This 
view fits with the phenotype observed in Myf5 and MyoD mutant embryos. The 
former present initially epaxial muscles defects, the latter a delayed myogenesis 
in the limbs. In both cases the residual myogenic determination genes are able 
to support an almost normal skeletal muscle development. (Hadchouel et al., 
2003; Kablar et al., 1997; Rudnicki et al., 1992) Interestingly distinct cis-
regulatory elements controlling the expression of Myf5 in different portions of 
the myotome have been identified. More recently the transcription factors En1 
and Sim1 have been proposed as markers respectively of the epaxial and 
hypaxial portion of the dermomyotome in the chick. 
At the limb level myogenic progenitors delaminate from the ventro-lateral 
domain of the dermomyotome (hypaxial) and migrate distally to the limb bud 
were they start to express the myogenic determination genes. Once activated 
myogenic program, myoblasts differentiate and fuse into discrete clusters, 
corresponding to the major muscle masses of the dorsal and ventral aspects of 
the developing limb. Subsequent phases of myogenesis (secondary and post-
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natal) will generate the definitive limb muscles. These migrating myogenic 
progenitor cells express several specific genes, which are essential for their 
migration and morphogenesis: (Birchmeier and Brohmann, 2000; Francis-West 
et al., 2003) Pax3 is expressed in the entire dermomyotome, but its expression 
is up-regulated laterally. (Goulding and Paquette, 1994) In the absence of Pax3 
and its downstream target c-met, the limb myogenic progenitors in the lateral 
dermomyotome are not able to undergo a normal delamination and migration.  
(Epstein et al., 1996; Relaix et al., 2004) Following inactivation of the Lbx1 
gene, which is, like c-met, a target of Pax3, the premyogenic cells delaminate 
appropriately, but appear unable to migrate. (Gross et al., 2000) A phenotype 
similar has been observed in animals in which the c-met signalling transducer 
Gab1 has been mutated. (Sachs et al., 2000) Mice mutant for Mox2 present a 
down-regulation of the expression of Myf5 and Pax3 and perturbations at the 
level of subsets of limb muscles. (Mankoo et al., 1999) Interestingly at least a 
subset of premyogenic cells migrating to the limb express the transcriptional 
repressor Msx1, which has been shown to block myogenic differentiation. 
During delamination, migration and differentiation (Bendall et al., 1999) 
premyogenic limb cells receive signals from the surrounding tissues (i.e. lateral 
plate mesoderm, apical ectoderm ridge, limb ectoderm and mesenchime). 
Scatter factor (the ligand of c-met), (Heymann et al., 1996)Fibroblast growth 
factors (FGFs), Shh, (Amthor et al., 1998)Bone morphogenic proteins (BMPs) 
(Amthor et al., 1998) and other members of the TGFβ superfamily appear to be 
involved. (Francis-West et al., 2003)Migratory myogenic progenitors are not 
present only at the limb level, but also in the lateral domain of the 
occipital/cervical somites from which migrate to contribute to the muscles of the 
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tongue and larynx. The progenitors involved in this process are characterized, 
as the limb premyogenic cells, by the expression of Lbx1. On the contrary 
hypaxial progenitors located at the interlimb level don’t express Lbx1. Instead of 
undergoing a long range migration, they enter into the ventral part of the 
underlying myotome and progressively extend ventrally to generate the hypaxial 
body wall and intercostal muscles. Interestingly, this strategy is adopted in the 
developing fin bud of the spotted dog fish shark (Scyliorhinus canicula), 
whereas the teleost zebrafish use the migratory mode similarly to amniotes. 
(Neyt et al., 2000) These observations suggest that the interlimb-level somites 
of amniotes and teleosts have conserved the primitive mode of hypaxial muscle 
formation and that the migratory strategy observed at the limb level was 
generated before the evolution of the tetrapod limb (i.e. is already present in 
zebrafish) (Hollway and Currie, 2005; Neyt et al., 2000) 
 
 
common to extrafusal fibers (Kucera and Walro, 1995; Kucera
and Walro, 1990b) and that expression of developmental MyHC
isoforms could be maintained in intrafusal fibers. In particular,
these differences in MyHC profile between extrafusal and
intrafusal fibers are thought to depend, at least in part, on the
action of sensory innervation (Kucera and Walro, 1988).
Anatomical heterogeneity in skeletal muscle
Epaxial and hypaxial myogenesis
A complex array of muscles is present in the vertebrate body.
Based on their innervation pattern it is possible to distinguish
epaxial muscles, which are innervated by the dorsal branch of
the spinal nerves, and hypaxial muscles, innervated by the ven-
tral branch. Epaxial muscles are located dorsally and correspond
to the deep muscles of the back in amniotes, whereas hypaxial
muscles are located superficially, laterally and ventrally and
include the diaphragm, body wall and limb muscles. In am-
niotes all of the trunk muscles are derived from the somitic
dermomyotome. Myogenic progenitors derived from the der-
momyoto e give rise to the myotome, located between the
dermomyotome and the medio-ventrally located sclerotome. In
addition, some progenitors und rgo a vent al migration t wards
sites of hypaxial myogenesis such as the limb or the tongue.
Each dermomyotome and myotome can be subdivided into a
more ventro-laterally located hypaxial region which gives rise
to hypaxial muscles and an epaxial region located dorso-ven-
trally from which the epaxial muscles are formed (reviewed in
Cossu et al., 2000). Work from several laboratories has shown
that only the precursors of the epaxial muscles are dependent
upon signals from axial structures, whereas precursors of the
hypaxial muscles do not require neural tube and notochord for
the myogenic commitment, but rather require signals from the
dorsal ectoderm (Fig. 3). In particular, it has been shown that
axial structures, probably through the release of Shh and Wnt1,
preferentially activate a myogenic program by inducing Myf5
expression. In contrast, dorsal ectoderm activates the myogenic
program through a M oD-mediated pathway by releasing
Wnt7a (reviewed in Cossu and Borello, 1999; Cossu et al.,
2000). This is consistent with the phenotype observed in Myf5
and MyoD knockout embryos since the former have early
epaxial muscle defects, whereas the latter show delayed myo-
genesis in the limbs. In both cases the other myogenic deter-
mination genes are able to support an almost normal skeletal
muscle development (Kablar et al., 1997; Rudnicki et al., 1992).
Interestingly, distinct cis-regulatory elements controlling the
expression of Myf5 in different portions of the myotome have
been identified (Hadchouel et al., 2003), and more recently, the
transcription factors En1 and Sim1 have been proposed as
markers respectively of the epaxial and hypaxial portion of the
dermo yotome in the chick (Cheng et al., 2004b) (Fig. 4).
At the limb level, myogenic progenitors delaminate from the
ventr -lateral domain of the dermomyotome (hypaxial region)
and migrate distally to the limb bud where they start to express
the myogenic d termin tion genes. Once the myogenic program
has been activated, the myoblasts differentiate and fuse into
discrete clusters, corresponding to the major muscle masses of
the dorsal and ventral aspects of the developing limb where
successive phases of myogenesis (secondary and postnatal)
generate the definitive limb muscles. These migrating myogenic
progenitor cells express several different genes, which are
essential for their function (Dietrich, 1999; Francis-West et al.,
2003). Pax3 is expressed throughout the entire dermomyotome,
Fig. 4. Epaxial and hypaxial myogenesis. (A) Model showing the early phases of myogenesis. Myotomal cells and embryonic myoblasts, specified from a Pax3/Pax7+
population of progenitors, invade the area between the dermomyotome and the sclerotome generating the myotome. The dorso-medial domain of the myotome/
dermomyotome will give rise to the epaxial (back) muscles, whereas from the ventro-lateral domain the hypaxial muscles will be generated. Surrounding tissues induce
myogenesis in the epaxial and hypaxial domains with different mechanisms involving different molecules (see text). At the limb level Pax3+, MRFs− progenitors
migrate from the ventro-lateral (hypaxial) domain of the dermomytome to the limbs, where they activate the myogenic program. Different signaling molecules such as
FGFs, BMPs and Scatter Factor (SF) are likely to regulate these events. (B) X-Gal staining of a Myf5+/nlacZ E11.5 embryo (Tajbakhsh et al., 1996). β-Galactosidase
expression marks the areas of the embryo where the myogenic program is activated. Abbreviations used: DM dermomyotome; NT neural tube; NC notochord; DE
dorsal ectoderm; LM lateral mesoderm; MRFs myogenic regulatory factors; BA branchial arches, HC hypoglossal cord; FL forelimb; HL hind limb.
287S. Biressi et al. / Developmental Biology 308 (2007) 281–293
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Figure 1.4.1 Epaxial and hypaxial myogenesis.  
(A) Model showing the early phases of myogenesis. Myotomal cells and embryonic 
myoblasts, specified from a Pax3/Pax7+ population of progenitors, invade the area between the 
dermomyotome and the sclerotome generating the myotome. The dorso-medial domain of the 
myotome/dermomyotome will give rise to the epaxial (back) muscles, whereas from the ventro-
lateral domain the hypaxial muscles will be generated. Surrounding tissues induce myogenesis 
in the epaxial and hypaxial domains with different mechanisms involving different molecules 
(see text). At the limb level Pax3+, MRFs− progenitors migrate from the ventro-lateral (hypaxial) 
domain of the dermomytome to the limbs, where they activate the myogenic program. Different 
signaling molecules such as FGFs, BMPs and Scatter Factor (SF) are likely to regulate these 
events. 
 
1.4.2 Rostro-caudal identity 
Although morphologically very similar, somites differentiate into distinct 
mesodermal tissues, depending on their axial level. The identity of the somite is 
specified by their unique combinatorial expression of HOX genes, which is 
generally referred as “HOX code”. (Burke et al., 1995; Kessel and Gruss, 
1991)Classical transplantation experiments clearly indicated that this segmental 
identity is able to influence the fate of sclerotomal (vertebrae and ribs) and non-
myogenic dermomyotomal (back dermis and scapula) derivatives of the 
somite.(Ehehalt et al., 2004; Jacob et al., 1975; Kieny et al., 1972) On the 
contrary, for many years it has been generally accepted that somitic myogenic 
precursors are completely naive, do not possess positional information and 
depend exclusively on extrinsic cues for their site-specific fate. This view was 
based on classical embryological experiments in the chick, in which somites 
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(Christ et al., 1977)were heterotopically transplanted at the limb level and the 
generation of graft-derived appendicular muscles could be observed. Although 
a few reports already suggested that myogenic precursors in the somite could 
also have a positional identity (Grieshammer et al., 1992; Murakami and 
Nakamura, 1991) only a recent paper  completely changed the traditional view. 
With an elegant transplantation approach Alvares and coworkers clearly 
showed that the competence to either generate migratory (Lbx1+) or non-
migratory (Lbx1-) muscle precursors depends on intrinsic values of the somite. 
Moreover they show that limbs contain a potent signalling mechanism (i.e. 
FGFs) that can override the non-migratory program of flank somites and induce 
in the myogenic progenitors the expression of the migration marker Lbx1. They 
also showed that the somitic predisposition toward a particular myogenic 
program (migratory or not migratory) directly or indirectly depends on Hox 
genes. These observation indicate that results obtained by heterotopic grafting 
into the limb area (Christ et al., 1977) can not be generalized for other axial 
levels and conclusively demonstrate that the axial identity to the somites, 
conferred by HOX genes, can determine the fate also of skeletal muscle 
precursors. Nevertheless whether this positional information is intrinsically 
encoded in myoblasts or in neighbouring cells of the same somite remains still 
unknown.  
1.4.3 Lateral asymmetry in the skeletal muscle 
The vertebrate body shows left-right asymmetry along the body axis. This 
is clearly evident from the organisation and anatomical localisation of different 
organs, such as heart, stomach, intestines, liver and lungs. (Beddington and 
Robertson, 1999) Skeletal myogenesis is generally thought to occur 
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symmetrically. Differences in the strength and size of muscles between the right 
and left are well known in humans, (Beddington and Robertson, 1999; Chhibber 
and Singh, 1970)although it is likely that they simply depend on training and 
lifestyle and not on a developmental process. Nevertheless in a recent work 
Golding and colleagues observed an asymmetric expression of myosin light 
chain 3F (MLC3F) and α-skeletal actin during the generation of the primary 
myotome. (Golding et al., 2004) This asymmetric expression appears to be 
transient and do not continue during primary myogenesis. Although the 
significance of this phenomenon remains unclear, it reveals that novel aspects 
of left-right asymmetry may involve also skeletal muscle development. 
 
1.5 Molecular mechanisms in skeletal muscle determination and 
differentiation 
1.5.1 Myogenic regulatory factors 
Skeletal muscle development in vertebrates occurs in several steps: 
mesoderm-derived precursors became committed to the myogenic lineage, 
develop into myoblast, which became post-mitotic and differentiate fusing 
together. This process leads to the generation of terminally differentiated 
multinucleated myotubes expressing a characteristic set of myofibrillar proteins 
(i.e. myosin heavy and light chains, tropomyosin, components of the troponin 
complex, sarcoplasmatic reticulum ATPase, Z line and M line proteins), which 
confer to the mature fibres the capacity to contract. The muscle regulatory 
factors (MRFs) are key regulators of the myogenic program. In vertebrates, four 
MRF genes have been identified: MyoD (Myf3), Myf5, Mfr4 (Myf6/herculin), 
Myogenin (Myf1). (Braun et al., 1989a; Braun et al., 1989b)MRFs are 
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specifically expressed in the skeletal muscle lineage. When transfected in 
fibroblasts and other cellular types MRFs can convert them to a myogenic fate. 
Moreover they have the capacity to activate their own expression and to 
crossactivate the other MRFs. They form heterodimers with a ubiquitous class 
of bHLH transcription factors known as E proteins  and bind a consensus DNA 
sequence called E-box (CANNTG) in the control regions of muscle-specific 
genes. Myf5 appears in the rostral somites of the mouse around 8 d.p.c., 
Myogenin at around 8.5 d.p.c., followed by MRF4 (9.5 d.p.c.) and MyoD, which 
appears at about 10.5 d.p.c. MyoD-/- mice show a delayed differentiation of 
limb muscle and an enhanced Myf5 expression during the embryonic stage of 
development. (Kassar-Duchossoy et al., 2004) Nevertheless after birth they 
appear grossly normal. (Rudnicki et al., 1992)Similarly in adult Myf5 -/- mice no 
striking muscular defects could be observed, although a defective myotome 
formation could be clearly noticed at the embryonic stage. Mrf4 -/- mice also 
present a mild phenotype, showing an increase in the expression of Myogenin. 
Embryos, in which the expression of MyoD, Myf5 and Mrf4 was simultaneously 
ablated, completely lack of skeletal muscle in any anatomical location and die at 
birth because of respiratory failure. (Kassar-Duchossoy et al., 2004) When the 
expression of both Myf5 and Mrf4 was down-regulated mice showed a severely 
delayed myotome formation but subsequent muscle development occurred 
relatively normal. (Braun et al., 1992; Kassar-Duchossoy et al., 2004; 
Tajbakhsh et al., 1996)Myogenin -/- mice form Myf5 and MyoD expressing 
muscle progenitors, but are deficient in differentiated muscle and die at birth. In 
particular secondary myogenesis appear to be affected in Myogenin -/- mice. 
Similarly in Myf5-/-: MyoD-/- mice secondary, but not trunk primary myogenesis, 
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appears to be completely abolished. (Kassar-Duchossoy et al., 2004; Valdez et 
al., 2000) Notably MyoD-/- :MRF4 -/- and MRF4-/-:Myogenin-/- double mutant 
embryos present a phenotype similar to Myogenin -/-. Also in MyoD-/-: 
Myogenin-/- and Myf5-/-: Myogenin-/- double mutant mice the muscle deficit at 
birth seems not to be significantly more severe than in single Myogenin-/- mice. 
On the contrary MRF4-/-: Myogenin-/-:Myod-/-triple mutant posses normal 
numbers of progenitors, but fail to form any differentiated muscle fibres either in 
vivo or in vitro.(Valdez et al., 2000) All together these reports suggest that Myf5, 
MyoD and Mrf4 can independently begin the myogenic program and thus act as 
myogenic “determination” genes during primary myogenesis, whereas only 
Myf5 and MyoD can exert this role during secondary myogenesis. (Kassar-
Duchossoy et al., 2004) On the contrary it is likely that Myogenin operate 
downstream to Myf5, MyoD and Mrf4 (at least during primary) by promoting 
muscle differentiation, a role that Myf5 appear not to be able to exert alone. 
(Valdez et al., 2000)Interestingly, introduction of the Myogenin cDNA into the 
Myf5 locus is unable to fully compensate for the absence of Myf5. Finally, in 
absence of Myogenin residual muscle fibres are present in vivo and an efficient 
generation of multinucleated myotubes could be observed in vitro suggesting 
that MyoD and Mrf4 could partially substitute for the absence of Myogenin. 
1.5.2 Regulation of expression and function of MRFs 
Pax3 and its paralogue Pax7 have been implicated in the specification of cells 
that will enter the myogenic program. It has been suggested that embryonic, 
foetal myoblasts and satellite cells could all derive from Pax3/Pax7 positive 
population of myogenic progenitors. (Kassar-Duchossoy et al., 2004; Relaix et 
al., 2005; Schienda et al., 2006)In contrast to MRFs, Pax3 and Pax7 are not 
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muscle specific. Nevertheless in absence of Pax3, Myf5 and Mrf4 the 
expression of MyoD and the myogenic program fails to be activated in the trunk 
(Tajbakhsh S, 1997), indicating that Pax3 (and Myf5) act upstream to MyoD. In 
an independent study, ectopic expression of Pax3 in embryonic tissues was 
shown to induce the expression of MyoD and Myf5. (Maroto et al., 1997) Pax3 
functions in cooperation with other protein, such as Dach2, Six1, 2, Eya 2 and 
4. (Relaix and Buckingham, 1999) 
All MRFs bind E-box sequences motif. Therefore, additional transcription 
factors are required to regulate MRF specificity for particular target genes. One 
such factor is MEF2. There are four MEF2 family members: Mef2A, Mef2B, 
Mef2C and Mef2D. They directly interact with MRFs and synergise with the 
MyoD-E12 heterodimer. (Black et al., 1998; Black and Olson, 1998)Moreover 
Mef2 genes are targets of the myogenic bHLH proteins and Mef2 proteins 
appear to control Mrfs expression. Similarly to Mef2 protein Serum response 
factor and muscle LIM protein appear to cooperate with Mrfs. MyoD has been 
shown to directly interact with p300/CBP, suggesting that the induction of the 
myogenic program by MyoD imply chromatin remodelling events. MRFs have 
been shown to be negatively regulated by several proteins. The HLH proteins Id 
and mTwist act in a dominant negative manner by sequestering E proteins and 
preventing their association with MRFs. Moreover the bHLH factor Mist1 has 
been shown to interact with MyoD and prevent its binding to the DNA. The 
transcriptional inhibitor Msx1 appears to be able not only to inhibit 
differentiation, but also to induce the reversal of terminal differentiation. 
Moreover MRFs activity is potentially negatively regulated by phosphorylation 
and appear to be tightly coupled to the cell cycle. Thus myogenesis appears to 
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be a process involving different cellular types whose fate is finely regulated by 
complex molecular mechanisms involving the interaction between the key 
regulators MRFs (Groisman et al., 1996) and a set of accessory proteins, which 
are important for the correct development of the muscles. 
1.6 Notch signalling 
Notch signaling is evolutionarily conserved and operates in many cell 
types and at various stages during development. Notch signaling must therefore 
be able to generate appropriate signaling outputs in a variety of cellular 
contexts. This need for versatility in Notch signaling is in apparent contrast to 
the simple molecular design of the core pathway.(Andersson et al., 2011) In 
mammals, there are four Notch receptors (Notch1-4) and five canonical ligands 
of the Delta-Serrate-Lag (DSL) type [Jag1 and Jag2 and delta-like 1 (Dll1), Dll3 
and Dll4] (reviewed by(D'Souza et al., 2010). This generates a large number of 
receptor-ligand combinations, which could potentially generate distinct 
responses. There is, however, little evidence for differences in signaling output 
between particular receptor-ligand combinations, with the notable exception of 
Dll3, which is the most structurally divergent ligand and lacks an extracellular 
Delta and OSM-11-like protein (DOS) domain as well as lysine residues in the 
intracellular domain (Dunwoodie et al., 1997) Dll3 is incapable of activating 
Notch receptors in trans (Ladi et al., 2005)and is rarely, if ever, present at the 
cell surface (Chapman et al., 2011; Geffers et al., 2007) 
The Notch ligand Dll4 is essential for vascular formation. (Shutter et al., 
2000)When Dll4 is inhibited in developing mouse retinas or in xenograft tumor 
models such as colon and lung carcinoma, excessive proliferation of 
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nonfunctional vasculature occurs. Blood vessels become unorganized and 
display increased sprouting and microvessel density, but decreased perfusion 
and function. The etiology of this seemingly paradoxical situation of more 
vessels but less perfusion and the reason for the decreased functionality are 
poorly understood. The microvessels created by the hyperproliferation of 
endothelial cells in the absence of Dll4 are immature; they lack coverage by α-
smooth muscle actin+ (α-SMA+) cells. A correlation between Dll4 expression 
and blood vessel maturation in bladder cancer has been demonstrated: 98.7% 
of Dll4+ tumor vessels were surrounded by α-SMA+ pericytes/vSMCs, while only 
64.5% of Dll4− vessels had α-SMA+ cell coverage. These data suggest that Dll4 
may play a role in the formation of-cell–derived pericytes/vSMCs during 
vasculogenesis, and also that Dll4 secreted by endothelial tip cells could be the 
signal to recruit pericytes from the sorrounding mesoderm. 
Mature blood vessels are composed of a single layer of endothelial cells, 
which form the inner tube of the vessel, surrounded by a supportive layer(s) of 
pericytes/vascular smooth muscle cells (vSMCs). Pericytes/vSMCs provide 
vessel structural support and contribute to the regulation of blood flow. In 
addition, pericytes/vSMCs provide growth and survival factors such as vascular 
endothelial growth factor (VEGF), fibroblast growth factor (FGF2), and 
angiopoietin (Ang1) to endothelial cells, while preventing endothelial cell 
hyperproliferation. Thus, pericytes/vSMCs help to maintain a stable state of 
functional, nonproliferative, mature vasculature. (Bergers and Song, 2005; 
Hirschi et al., 1998)Without pericytes/vSMCs, blood vessels are leaky, less 
stable, and more susceptible to antiangiogenic therapies and regression due to 
pathologic conditions such as hyperoxia.(Abramovitch et al., 1999) 
 44	  
A functional vascular network is essential for the growth of solid tumors. 
Two of the processes by which tumors can form vessels are angiogenesis, the 
sprouting of preexisting blood vessels, and vasculogenesis, the recruitment of 
bone marrow (BM) cells to the tumor with subsequent formation of a de novo 
vessel network. During vasculogenesis, BM cells migrate to the tumor, adhere 
to sites of developing vasculature, and contribute to the endothelial and 
pericyte/vSMC populations within mature vasculature. One molecular 
mechanism likely to contribute to the process of recruitment of pericytes by 
endothelial cells is delta-like ligand 4 (Dll4)–Notch signaling, that is one of the 
four Notch ligands existing in mammals. All ligands and receptors are 
membrane bound and signal by cell-to-cell contact. When a ligand binds to a 
receptor, 2 cleavage events occur to activate receptor signaling. The Notch 
intracellular domain (NICD) is released by the second cleavage event, which is 
mediated by the γ-secretase complex. NICD is then translocated to the nucleus, 
where it forms a transcriptional activating complex that includes recombination 
signal-binding protein-Jκ (RBP-Jκ) and mastermind-like protein (MAML). The 
NICD-RBP-Jκ-MAML complex induces transcription of Notch effectors such as 
the Hes and Hey family members, which are themselves transcription factors 
that go on to regulate the expression of downstream Notch targets. 
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Figure 1.6.1  
The newly translated Notch receptor protein is glycosylated by the enzymes O- fut and Rumi, 
which are essential for the production of a fully functional receptor.  Mature receptor is produced 
after proteolytic cleavage by PC5/furin at site 1 (S1). It is then targeted to the cell surface as a 
heterodimer that is held together by noncovalent interactions. In cells expressing the 
glycosyltransferase Fringe, the O-fucose is extended by Fringe enzymatic activity, thereby 
altering the ability of specific ligands to activate Notch.  Notch receptor is activated by binding to 
a ligand presented by a neighboring cell. Endocytosis and membrane trafficking regulate ligand 
and receptor availability at the cell surface. Ligand endocytosis is also thought to generate 
mechanical force to promote a conformational change in the bound Notch receptor. This 
conformational change exposes site 2 (S2) in Notch for cleavage by ADAM metalloproteases 
(perhaps after heterodimer dissociation at site 1). γ-Secretase then cleaves the Notch 
transmembrane domain in NEXT progressively from site 3 (S3) to site 4 (S4) to release the 
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unique negative regulatory region (NRR), which is composed 
of three cysteine-rich Lin12-Notch repeats (LNR) and a het-
erodimerization domain (Figure 2A). The negative regulatory 
region plays a critical role in preventing receptor activation in 
the absence of ligands and will be discussed in detail later. 
Most surface Notch proteins are cleaved by furin-like con-
vertases within the secretory pathway (Figure 1) at site 1 (S1) 
located within an unstructured loop that protrudes from the 
heterodimerization domain. This cleavage event converts the 
Notch polypeptide into an NECD-NTMIC (Notch extracellular 
domain-Notch transmembrane and intracellular domain) het-
erodimer held together by noncovalent interactions between 
the N- and C-terminal halves of the heterodimerization domain 
(Figures 1 and 2A).
The single transmembrane domain of the Notch receptor 
ends with a C-terminal “stop translocation” signal comprised 
of 3–4 arginine/lysine (Arg/Lys) residues. Intracellularly, the 
RAM (RBPjN association module) domain forms a high-
af!nity binding module of 12–20 amino acids centered on a 
conserved WxP (tryptophan-any amino acid-proline) motif. 
A long, unstructured linker containing a nuclear localization 
sequence links the RAM domain to seven ankyrin repeats 
(ANK domain). Following the ANK domain is an additional 
bipartite nuclear localization sequence and a loosely de!ned 
and evolutionarily divergent transactivation domain. The very 
C terminus of the receptor contains conserved proline/glu-
tamic acid/serine/threonine-rich motifs (PEST) that harbor 
degradation signals (degrons), which regulate the stability of 
NICD. Drosophila Notch also contains a glutamine-rich repeat 
(OPA) (Figure 2A).
Our understanding of Notch ligands is rapidly evolving. Most 
Notch ligands are themselves type I transmembrane proteins 
(Figure 2B) (reviewed in D’Souza et al., 2008). Recent studies 
have re!ned our understanding of their structure and func-
tion (Cordle et al., 2008a; Komatsu et al., 2008). The largest 
class of Notch ligands is characterized by three related struc-
tural motifs: an N-terminal DSL (Delta/Serrate/LAG-2) motif, 
specialized tandem EGF repeats called the DOS (Delta and 
OSM-11-like proteins) domain (Komatsu et al., 2008), and EGF-
like repeats (both calcium binding and non-calcium binding) 
(Figure 2B). DSL ligands can be classi!ed on the basis of the 
presence or absence of a cysteine-rich domain (Jagged/Ser-
rate or Delta, respectively) and the presence or absence of a 
DOS domain (Figure 2B). As we will detail later, both the DSL 
and DOS domains are involved in receptor binding. Additional 
proteins lacking DSL and DOS domains have been reported to 
act as noncanonical ligands for Notch receptors in the central 
nervous system and in cultured cells (for example, F3/Contac-
tin1, NB-3/Contactin6, DNER, MAGP1, and MAGP2) (Figure 
2B, Table 1) (reviewed in D’Souza et al., 2008). However, these 
activities have been largely unexplored, and the physiological 
functions for these proteins in the Notch pathway remain to be 
elucidated.
It is now well established that Notch receptor activation 
is mediated by a sequence of proteolytic events (Figures 1 
and 2A) (reviewed in Bray, 2006). Ligand binding leads to 
the cleavage of Notch by ADAM (a disintegrin and metal-
loprotease) proteases at site 2 (S2), located ?12 amino 
acids before the transmembrane domain and deeply bur-
ied within the negative regulatory region (Figures 2 and 3A). 
Site 2 cleavage is a key regulatory step in Notch activa-
tion, but some ambiguity still exists regarding the enzymes 
that mediate cleavage. Indeed, only ADAM17/TACE (tumor 
Figure 1. The Core Notch Signaling Pathway Is Mediated by 
 Regulated Proteolysis
The newly translated Notch receptor protein is glycosylated by the enzymes O-
fut and Rumi, which are essential for the production of a fully functional recep-
tor. The mature receptor is produced after proteolytic cleavage by PC5/furin at 
site 1 (S1). It is then targeted to the cell surface as a heterodimer that is held to-
gether by noncovalent interactions. In cells expressing the glycosyltransferase 
Fringe, the O-fucose is extended by Fringe enzymatic activity, thereby altering 
the ability of speci!c ligands to activate Notch. The Notch receptor is activated 
by binding t  a l gand presented by a neighboring cell. Endocytosis and mem-
brane traf!cking regulate ligand and receptor availability at the cell surface. 
Ligand endocytosis is also thought to generate mechanical force to promote 
a conformational change in the bound Notch receptor. This conformational 
change exposes site 2 (S2) in Notch for cleavage by ADAM metalloproteases 
(perhaps after heterodimer dissociation at site 1). Juxtamembrane Notch cleav-
age at site 2 generates the membrane-anchored Notch extracellular truncation 
(NEXT) fragment, a sub trate or the J-secretase complex. J-Secretase th n 
cleaves the Notch transmembrane domain in NEXT progressively from site 
3 (S3) to site 4 (S4) to release the Notch intracellular domain (NICD) and NE 
peptide. J-Secretase cleavage can occur at the cell surface or in endosomal 
compartments, but cleavage at the membrane favors the production of a more 
stable form of NICD. NICD then enters the nucleus where it associates with the 
DNA-binding protein CSL (CBF1/RBPjN/Su(H)/Lag-1). In the absence of NICD, 
CSL may associate with ubiquit us corepressor (Co-R) proteins and histon  
deacetylases (HDACs) to repress transcription of some target genes. Upon 
NICD binding, allosteric changes may occur in CSL that facilitate displacement 
of transcriptional repressors. The transcriptional coactivator Mastermind (MAM) 
then recognizes the NICD/CSL interface, and this triprotein complex recruits 
additional coactivators (Co-A) to activate transcription.
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Notch intracellular domain (NICD) and Nβ peptide. γ-Secretase cleavage can occur at the cell 
surface or in endosomal compartments, but cleavage at the membrane favors the production of 
a more stable form of NICD. NICD then enters the nucleus where it associates with the DNA-
binding protein CSL (CBF1/RBPjκ/Su(H)/Lag-1). In the absence of NICD, CSL may associate 
with ubiquitous corepressor (Co-R) proteins and histone deacetylases (HDACs) to repress 
transcription of some target genes. Upon NICD binding, allosteric changes may occur in CSL 
that facilitate displacement of transcriptional repressors. The transcriptional coactivator 
Mastermind (MAM) then recognizes the NICD/CSL interface, and this triprotein complex recruits 
additional coactivators (Co-A) to activate transcription.  
1.7 Reprogramming 
1.7.1 Reprogramming to an embryonic-like state or directly to another 
mature cell 
Almost 20 years after MyoD discovery, Takahashi and Yamanaka showed 
that transduction of embryonic mouse fibroblasts with four transcription factors 
now known as the Yamanaka factors (Oct4, Klf4, cMyc and Sox2), reprograms 
somatic cells into an embryonic-like state: “induced Pluripotent Stem cells” or 
iPS cells, (Takahashi and Yamanaka, 2006)(Fig. 1). This discovery hit the field 
like an hurricane and the number of papers published yearly on the topic keeps 
increasing exponentially (for recent reviews see:(Hanna et al., 2010; Wilmut et 
al., 2011; Yamanaka and Blau, 2010). The possibility of deriving patient-specific 
ES-like cells that can be indefinitely expanded in vitro, genetically corrected if 
needed, and then induced to differentiate into the desired cell type, appeared as 
a real breakthrough over previous reprogramming approaches based on 
nuclear transfer; it is technically simpler and apparently bypasses the ethical 
controversies and their political consequences described above. For the sake of 
records, it should be mentioned that several recent papers have challenged the 
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complete equivalence of iPS and ES cells (for a recent review see:(Power and 
Rasko, 2011). Until now, the differences reported do not seem to have a major 
impact on the possible future clinical use of these cells, with the possible 
exception of immunogenicity. 
Moreover, the argument that the reprogrammed nucleus is anyway “old”, 
i.e. has the same age of the patient, appears to be at least disingenuous when 
compared to spared embryo derived ES cells, which are ”non-self”: a 
reprogrammed cell should be compared to a nuclear-transferred ES cells that 
has exactly the same age and “selfness”. Only time will tell whether iPS will 
replace ES cells, but in any case, the value of ES cells for science and 
medicine will remain immense, since they led to a revolution in biology, and the 
same iPS cells would have never been discovered without them. 
1.7.2 Direct reprogramming 
Finally, in the last two years, several laboratories showed that it is 
possible to directly reprogram an adult fibroblast to a cardiomyocyte or a neuron 
(and even specific neural subtypes), by forced expression of usually two or 
three transcription factors. (Ieda et al., 2010; Szabo et al., 2010; Vierbuchen et 
al., 2010) In all cases, and examples are accumulating at a weekly pace, cells 
repress their own transcriptional program and activate the new one without 
transiting through an ES-like state. Although many issues remain to be solved, 
e.g. frequency of complete terminal differentiation into the desired cell type, 
these data appear to move the field even further toward their safe use since the 
tumorigenic risk, associated with ES/ipS cells, would not exist anymore. 
Obviously, especially in the case of certain human cells, the total number of 
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cells that can be expanded in vitro would return as a problem due to the limited 
proliferation potency of human fibroblasts. Why earlier attempts (at the time of 
MyoD discovery) at directly reprogramming fibroblasts into other types of 
differentiated cells failed, and more recent, iPS cell-boosted attempts succeed, 
is probably due to the major advances in our understanding of the 
transcriptional machinery, that took place in the last twenty years. 
1.7.3 Environmental reprogramming 
Parallel to these events, and currently outdated by the development of 
molecular approaches, a flurry of data accumulated during decades of work 
showing that, following transplantation, embryonic or even adult cells, may 
change their fate and adopt that of the surrounding cells. Indeed, heterotopic 
transplantation of a group of cells, naturally fated to give rise to tissue A, into 
developing tissue B, is a classic assay for fate determination in embryology. If 
cells maintain the A phenotype, they are considered “determined” or 
“committed” to fate A, whereas if they turn into tissue B, they are considered 
“undetermined” and ready to be instructed by signals emanating from the extra-
cellular microenvironment. It is conceivable that these signalling molecules may 
lead to the activation of the same genes that, once transfected into adult 
fibroblasts in vitro, “reprogram” them to the desired cell fate.  
Despite the fact that the mammalian embryo is considered to be 
“regulative”, it was generally assumed, at least until Yamanaka’s work, that 
once committed, cells could only progress towards their fixed differentiation 
pathway or die. Yet, numerous examples of “spontaneous change of fate” exist 
in the old literature, but they are often linked to post-natal tissue damage and 
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regeneration. For example, retina regeneration by pigment cells in amphibians 
is a classic case of trans-differentiation (or “spontaneous reprogramming”) that 
only occurs after tissue damage. On the other hand, a spontaneous trans-
differentiation from smooth to skeletal muscle in the mouse oesophagus was 
reported in 1995 (Patapoutian et al., 1995) but later questioned based upon 
lineage tracing studies. (Rishniw et al., 2003) 
The field was changed in 1998, by a paper showing that the bone marrow 
of normal adult mice contains cells that can participate in skeletal muscle 
regeneration and give rise to new muscle fibre nuclei, (Ferrari et al., 1998; Ying 
et al., 2002) Bone marrow-derived muscle cells were very few (less than 1%) 
and were easily detected in the host muscle despite their low frequency, 
because they expressed a muscle-specific nuclear LacZ. Within a few years, 
the literature was flooded with papers, often in high profile journals (e.g., 
(Krause et al., 2001; Lagasse et al., 2000; Orlic et al., 2001)showing that many 
cells of adult tissues, when transplanted in a different regenerating tissue, may 
give rise to one or more cell types that are typical of that recipient environment. 
Often, conclusions were based on double fluorescence, where one cell would 
show a tracer of its origin and an antigen typical of the tissue where it had been 
transplanted. Nevertheless, these data suggested that it would have been 
possible to isolate patient’s own cells from an unaffected tissue, expand and, if 
needed, genetically correct them for transplantation into the affected tissue or 
organ. It was obvious that the frequency of these events was almost invariably 
very low, far below the threshold of any possible clinical efficacy.  The papers 
were heavily criticized. 
It was proposed that “plasticity” was the consequence of immune staining 
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or tissue culture artefacts, and explaining that the ones that were confirmed by 
other independent laboratories were the result of spontaneous cell fusion, 
where, as described above, one nucleus would impose its transcriptional 
program to the other. This culminated in three papers published at the same 
time and practically burying the field of environmental reprogramming and 
plasticity. (Terada et al., 2002; Wagers et al., 2002; Ying et al., 2002) The fact 
that spontaneous cell fusion is the natural mechanism through which skeletal 
muscle forms (Mintz and Baker, 1967) in vertebrates  was not considered at 
that time, even though it did explain, at least in part, the result of bone marrow 
giving rise to skeletal muscle (Ferrari et al. op.cit.), and later and unexpectedly, 
to Purkinjie cells. (Weimann et al., 2003)Nevertheless, years went by and 
“plasticity” remained a synonym for “artefact”. However, in recent years, several 
papers, scientifically unquestionable and in high profile journals, showed that 
cells can be environmentally reprogrammed to a complete and mature fate. For 
example, it was recently shown that nerve-derived Shh defines a niche that 
maintains hair follicle stem cells in their multipotent state, whereas in its 
absence, cells adopt an epidermal “only” fate. (Brownell et al., 2011) Even more 
strikingly, clonally expanded epithelial cells of both embryonic and adult rodent 
thymus were reprogrammed to multipotent hair follicle stem cells in vivo, as 
they were found able to give rise to all skin lineages, i.e. hair follicle, epidermis 
and sebaceous glands, upon serial transplantation. Moreover, reprogrammed 
thymic cells re-isolated from the hair follicle, were able, to a variable extent, to 
revert to their primitive fate once transplanted back into the thymus. (Bonfanti et 
al., 2010) Other examples keep accumulating, such as those showing extra-
cellular signals enhancing transcription factor-mediated reprogramming to iPS 
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(Lluis et al., 2008) or to another differentiated cell type .(Aviv et al., 2009) Also, 
pathological conditions such as atherosclerosis induce smooth muscle cells to 
differentiate into osteochondrogenic precursors and chondrocytes. (Speer et al., 
2009) Finally, it was also shown that physical cues, such as substrate stiffness 
may, by themselves, direct mesenchymal stem cell fate towards one or another 
differentiation pathway. (Engler et al., 2006) 
1.7.4 What is the difference between “direct reprogramming and 
environmental reprogramming”? 
“Plasticity”, defined as the ability of a cell to change its phenotype in 
response to both intra- or extra- cellular signals has now acquired a broad and 
ill-defined general meaning. It does not literally correspond to “trans-
differentiation”, because the latter only refers to already differentiated cells that 
directly switch to another differentiation program without regressing to an ES-
like state. Plasticity instead refers also to a still undifferentiated but “committed” 
cell, either embryonic or adult, that during its pathway towards the expected 
terminal differentiation can be diverted towards another type of terminal 
differentiation. At first sight, it would appear that approaches such as cell fusion, 
exposure to oocyte extract, and environmental cell reprogramming may be 
outdated by the most direct transfer of defined transcription factors. 
However, in our opinion, environmental reprogramming maintains an 
important role in stem cell biology for three main reasons. First, the mammalian 
body is composed of thousands of different cell types and we currently have the 
recipe to convert “fibroblasts” or direct ES/iPS towards a specific terminally 
differentiated cell (e.g. a dopaminergic neuron: (Caiazzo et al., 2011) only in a 
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handful of cases. The “environmental” approaches may still be invaluable to 
identify extra-cellular signals and downstream transcription factors that are 
required to obtain a functional beta or alpha cell of pancreatic islets or a cone or 
a cell of the heart conduction system. Second, evidence is accumulating that 
fusion may occur in vivo in many tissues, resulting in cell reprogramming and 
thus contributing to regeneration. (Sanges et al., 2011)Third and more 
importantly, environmental reprogramming may mimic in vitro, or following 
experimental transplantation, natural processes that occur in vivo, though likely 
at low frequency, and may be needed to finely tune the amount of progenitor 
cells that are distributed among neighbouring developing tissues. In this regard, 
we showed in the past that, upon transplantation, human pericytes from skeletal 
muscle are recruited to a skeletal muscle fate rather than following their default 
pathway, i.e. the formation of the smooth muscle layers surrounding the 
endothelium of blood vessels. (Dellavalle et al., 2007) We now have evidence 
that pericytes spontaneously change their fate, contributing to up to 7% of 
developing skeletal muscle fibres and 20% of their associated satellite cells 
during unperturbed post-natal development of the mouse. (Dellavalle et al., 
2011) This supports the hypothesis that pericytes represent a resident 
progenitor of post-natal tissues endowed with the potency to generate the 
differentiated cell types of that specific tissue.(Bianco et al., 2008) The 
implications of this concept for regenerative medicine can be already 
appreciated as a phase I/II clinical trial, based upon transplantation of 
mesoangioblasts (the in vitro counterpart of skeletal muscle pericytes) from 
HLA-identical donors, is ongoing at San Raffaele Hospital in Milan. It is 
important that the cells to be transplanted possess, as a natural developmental 
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option, the ability to give rise to the desired tissue, i.e. skeletal muscle in our 
case, at a frequency that might be clinically relevant.  
In conclusion, plasticity is not an artefact. It is likely a compensatory 
mechanism by which developing or regenerating tissues adjust their cell 
number. It is rare but important. It may occur by cell fusion or environmental 
reprogramming that are mimicked in the laboratory by transfer of nuclei or 
transcription factors. The years to come will likely provide answers to these 
intriguing issues that are crucial for the future of regenerative medicine. 
 
 
Figure 1.7.1  
Changing the model of cell determination and differentiation. Gray arrows indicate the ability of 
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ES and iPS cells to give rise to germ and somatic layers, that proceed (light blue arrows) 
towards their various differentiated tissues. Green arrows represent the possibility of 
reprogramming differentiated cells to a pluripotent state or directly to a different differentiated 
cell type, independently from the germ layer of origin (trans-differentiation). The debated 
equivalence of ES and iPS is indicated by the symbol “=” preceded by a question mark. 
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RATIONALE 
 Notch signaling is one of the most studied pathway during development. It 
exerts its function by controlling the balance between proliferation and 
differentiation. It prevents tumor formation and by the other hand the 
abundance of his control made the pathway really difficult to understand. 
On the contrary, skeletal muscle has some defined “dogma”. In fact, it is 
known that once a cell (suppose to be myogenic or not) enter myogenic 
program it is not possible to overcome the commitment; that’s why a myogenic 
cells has no different choice. In this year, however, seems that some myogenic 
progenitor, in particular Pax3 expressing cells, has the capability to migrate to t 
dorsal aorta, (Esner et al., 2006)so to originate vascular smooth muscle cells. 
Pericytes are a subset of cells that in this year start to purchase a lot of 
interests; in fact different works demostrate their capability of trans differentiate 
in some tissue likely they are resident progenitor of different tissue. Since 
myoblast and pericytes cooperate during muscle regeneration, this work aim to 
demostrate that this cooperation is not mutual exclusive: in fact, if pericytes can 
be recruited by mygenic cells to do muscle, this way pericyte, or better 
endothelium, can recruit myoblast to build a new vessel. In fact, during 
embryogenesis myoblast are in the mesenchyme surrounding vessels; so 
vessel, with proper signaling could recruit cells, this case myoblast, to become 
pericyte. To investigate this, we choose an in vitro model to obtain cells that 
could maintain embryonic property (cells sorted from Pax3GFP/+mouse) and an 
in vivo model to validate the data. Since tip cells, the cells responsible of 
pericytes recruitment by endothelium, secreted a Notch activator, signaling 
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used by endothelium is supposed to be Notch signaling; so we crossed two 
different mice, MyoDiCRE and ROSANICD to be sure that all myogenic cells 
activate Notch pathway. 
This work could be the first evidence of spontaneous reprogramming, and 
will demonstrate the capability of myogenic cells to exit the commitment and 
change their fate. 
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MATERIAL AND METHODS 
2.1 Mutant Animals and Genotyping 
The Pax3GFP-/+ mice (Relaix et al., 2005), MyoDiCre mice (Kanisicak et al., 2009), 
ROSANICD mice (Murtaugh et al. 2003), ROSAEYFP (Srinivas et al., 2001) and 
their genotyping strategies have been published. Expression of the transgene in 
the various tissues was evaluated by RT-PCR. All experiments were performed 
under internal regulations for animal care and handlings (IACUC 355). 
2.2 Cell isolation 
Embryonic myoblasts were isolated from E11.5 (after removal the neural tube) 
embryos; Pax3GFP-/+ embryos were distinguished from their wild-type littermates 
by examination under a fluorescence microscope. Embryonic myoblasts were 
obtained from dissection of somites and limbs of E11.5 embryos. Tissues were 
dissociated with 0.15 mg/ml collagenase Type V (Sigma), 0.4 mg/ml dispase 
(Gibco), 0.1 mg/ml Dnase I (Roche) in a buffered solution Hank's Balanced Salt 
Solution (HBSS; BioWhittaker) supplemented with 15 mM HEPES, 15 mM 
glucose, 1.5 mM MgSO4, 0.3% (W/V) bovine serum albumin (BSA), pH 7.4. 
Dissociated cells were resuspended in DMEM–high glucose (Gibco), 
supplemented with 20% fetal calf serum (FCS; BioWhittaker), 20 mM HEPES 
and 2 mM EDTA and filtered through 40-µm cell strainers (Falcon) before 
sorting using a Vantage Sorter SE (Becton-Dickinson) at a flow rate of 3000 
cells per second. GFP was exited at 488 nm using an argon laser. Specific 
green fluorescence, forward (FSC) and side (SSC) light scatter were measured. 
FSC and SSC parameters were used to gate out cell clumps and debris. Cells 
dissociated from wild-type littermates were used to set the gating to exclude 
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green autofluorescence. The purity of each sorted sample was evaluated by 
immediate reanalyzing of approximately 10,000 cells. 
2.3 Cell culture 
For the differentiation assay, sorted embryonic myoblasts were resuspended in 
DMEM–high glucose supplemented with 20% horse serum (BioWhittaker) and 
20 mM HEPES and spotted onto calf skin collagen (Sigma)- coated dishes, at a 
density of approximately 80,000 cells/cm2. 
To induce pericytes differentiation embryonic myoblast were plated onto Dll4 
(R&D SYSTEMS, 1389-D4) 10ug/mL coated dishes. Medium was composed by 
DMEM-high glucose supplemented with 20% horse serum and PDGF (SIGMA) 
50ug/mL. 
HUVECs were cultured in MCDB 131 with endothelial cell supplements as 
described previously (Lampugnani et al., 2003). For the experiments 1,800 and 
42,000 cells/cm2 were seeded to obtain sparse and confluent cultures, 
respectively. HUVECs were used till passage 4. 
2.4 Alkaline phosphatase reaction.  
Different kits for AP enzymatic detection were used (see below) to exploit 
different reaction colors. Sections or cells were fixed with PFA 4% at 4 °C for 10 
min and, after 3 washes, incubated with BCIP-NBT kit (Roche, 12296226 and 
12329020) in an alkaline buffer (NaCl 100 mM, Tris 100 mM PH 9.5, MgCl2 50 
mM, Tween 0.1%) for 20 min in the dark, or with PermaRed/AP (Histo-Line 
laboratories, K049) for 20 min. Moreover, AP substrate kit from Vector (SK-
5100) were used and visualized by confocal microscopy (Leica) at 456 nm, 
along with other immuofluorescent antibodies. 
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2.5 Immunofluorescence on Cultured Cell and Tissue Sections 
Frozen sections and cultured cells were fixed with PFA 4% at 4 °C for 10 min, 
washed 3× with Triton 0.2% BSA 1% in PBS, and incubated with the same 
buffer for 30 min, followed by 10% Donkey serum for 30 extra min. Primary 
antibody was incubated for 1 h at room temperature or O/N at 4 °C in the same 
buffer. Samples were washed 3 times and then incubated with secondary 
antibodies (Alexa Fluor 488-594-546 or 647, Invitrogen) for 1 h at RM, washed 
3 times and then mounted and examined under epifluorescence or confocal 
Leica microscope. When necessary, adjacent sections were stained with H&E. 
Immunofluorescent staining was carried out with the following antibodies: rabbit 
policlonal anti-Myf5 1:100 (Santa Cruz biotecnology), Rat policlonal anti-
PECAM 1:2 (gift from Elisabetta Dejana), mouse monoclonal anti-SMA 1:300 
(SIGMA), Goat policlonal anti-AP 1:100 (R&D SISTEMS) rabbit policlonal anti-
NG2 1:300 (Chemicon AB5320), anti-MyHC at 1:2 (MF20 DHSB), anti-GFP 
1:300 (Chemicon, AB3080) mouse monoclonal antiBV9 (gift from Elisabetta 
Dejana). 488,647 or 594-conjugated donkey anti-mouse. Hoechst was used to 
stain nuclei. 
 
2.6 RT-PCR 
The RNA was isolated from cells (sorted fraction from Pax3GFP/+ embryos) and 
embryos/foetus from mice at different developmental stages. One microgram of 
RNA, extracted with the RNeasy micro kit (QIAGEN) from cells or TRIZOL 
(Invitrogen) from tissues, was converted into double-stranded cDNA with the 
cDNA synthesis kit ImProm™-II Reverse Trascription System (Promega), 
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according to the manufacturer’s instructions. The primers used are described in 
the Supplementary materials and methods. 
2.7 Statistical analysis 
Data were analyzed using GraphPad Prism 5 and values were expressed as 
means ± standard error (SEM). Statistical significance was tested using 
Unpaired and Paired Student t-test or one-way ANOVA analysis of variance 
followed by Bonferroni multiple comparisons post-test. A probability of less than 
5% (P < 0.05) was considered to be statistically significant. 
2.8 Quantitative Real-Time PCR 
RNA was retrotrascribed as described above. Real time quantitative PCR were 
performed with a real-time PCR machine (Mx3000P; Stratagene). Each cDNA 
sample was amplified in triplicate using GoTaq® qPCR master mix (Promega). 
Data are expressed as mRNA levels relative to the house keeping gene Gapdh, 
or as the percentage of target gene mRNA levels relative to levels detected in 
their relative controls.  
2.9 Angiogenic assay 
Matrigel was incubated on ice at 4 degree O/N. Then it was transferred 150 ul 
of pre-cooled matrigel reduced Growth Factor  (BD matrigel™ 356230) to a 48-
well plate. All this passages has been performed on ice. Then the matrigel was 
solidify at 37 degree C for 30 min.  Endothelial cells were collected, count and 
dilute to 4 x 105 cells/ml in cell culture media mixture to the 48-well plate. 
HUVEC cells were cultured alone as control, then with not treated sorted cells 
and with treated Dll4 and PDGF-BB sorted cells. Incubate at 37 degree, 5% 
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CO2 for 3 to 30 h. Any increase or decrease in the formation of tubes in the test 
wells was compared to control wells (the one with non-treated cells) and this 
would indicate that the network is stable thanks to pericytes covering. 
2.9.1 Matrigel plug 
Matrigel reduced Growth Factor  (BD matrigel™ 356230)(500 uL) was injected 
subcutaneously in the dorsal region of 2.5–3.5 month old nude mice and 
permitted to solidify. In the plug there was mixed HUVEC cells plus Pax3GFP/+ 
cells treated with Dll4 and PDGF-BB. Mice were observed after 24 h to monitor 
condition of the wound. Plugs could be recovered for several weeks but 
typically we sacrifice the mice after 7 and 14 days. After the sacrifice plug was 
embedded in OCT . 
2.10 Protein Extraction and Western Blot 
Cells were lysed in boiling Sample Buffer 1  (50 mM Tris-HCl pH 6.8, 2%SDS, 
10% glycerol, 100 mM dithiothreitol (DTT)). 30-50 ug of protein were resolved 
on 8% or 12% SDS-PAGE (according to the different molecular weights) and 
then transferred onto nitrocellulose. After saturation in 5% milk in tris-buffered 
saline (TBS)-T (TBS plus 0.02% Tween20), filters were incubated with the 
following antibodies: monoclonal anti-MyHC, monoclonal anti-Myogenin, rabbit 
polyclonal anti-Ng2, goat policlonal anti-TNAP (sc-718), rabbit polyclonal anti-
PDGFR, mouse monoclonal anti-MyoD antibody policlonal anti-Myf5, mouse 
monoclonal anti-tubulin (ICN), mouse monoclonal anti-GAPDH. After washing, 
membranes were incubated with horseradish-peroxidase-conjugated species-
specific secondary antibodies (BIO-RAD) followed by enhanced 
chemiluminescence system (Amersham). 
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2.12 Supplemental information 
 
• Myf5 (351bp) 
 
   forward TGCCATCCGCTACATTGAGAG  
   reverse  CCGGGGTAGCAGGCTGTGAGTTG 
 
 
• MyoD (396bp) 
 
   forward GCCCGCGCTCCAACTGCTCTGAT 
   reverse CCTACGGTGGTGCGCCCTCTGC 
 
 
• MyHC (160bp) 
 
   forward GGCCAAAATCAAAGAGGTGA 
   reverse CGTGCTTCTCCTTCTCAACC 
 
 
• Myogenin (156bp) 
 
   forward GACATCCCCCTATTTCTACCA 
   reverse GTCCCCAGTCCCTTTTCTTC 
 
 
• MRF4 (235bp) 
 
   forward GAGCTGGGCGTGGACCCCTA 
   reverse CCACGCTGGGGAGTTTGCGT 
 
 
• NG2 (443bp) 
 
   forward ACAAGCGTGGCAACTTTATC 
   reverse ATAGACCTCTTCTTCATATT 
 
 
• AP (329bp) 
 
   forward GTGGATACACCCCCCGGGGC 
   reverse GGTCAAGGTTGGCCCCAATGCA 
 
 
• PDGFbeta (88bp) 
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   forward AAGTTTAAGCACACCCATGACAAG 
   reverse ATTAAATAACCCTGCCCACACTCT 
 
• RGS5 (110bp) 
 
   forward GCTTTGACTTGGCCCAGAAA 
   reverse CCTGACCAGATGACTACTTGATTAGC 
 
• ID1 (210bp) 
 
   forward CGCAAAGTGAGCAAGGTGGAGA 
   reverse TCAGCGACACAAGATGCGATC 
 
 
• ID2 (264bp) 
 
   forward GCCCAGCATCCCCCAGAA 
   reverse CCATTTATTTAGCCACAG 
 
 
• ID3 (225bp) 
 
   forward ACAGCTGAGCTCACTCCGGAACT 
   reverse TCCAGCCTCGAGGCGTTGAGTT 
 
 
• Twist (197bp) 
 
   forward CACGCTGCCCTCGGACAA 
   reverse GGGACGCGGACATGGACC 
 
 
• Notch1 (202bp) 
 
   forward TGGACGCCGCTGTGAGTCA 
   reverse TGGGCCCGAGATGCATGTA 
 
 
• Notch3 (218bp) 
 
   forward CCTGGATGCTGGGGCGGACAC 
   reverse CGGCAT GGCTGGCGATGAGCT 
 
 
• Gapdh (250bp) 
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   forward TTCACCACCATGGAGAAGGC 
   reverse GGCATGGACTGTGGTCATGA 
 
• Pax3 (413bp) 
 
   forward GAGACTGCCTCCATACGTCC 
   reverse ACGGTGTTTCGATCACAGAC 
 
• Pax7 (282bp) 
 
   forward GTGGGGTCTTCATCAACGGTC 
   reverse GCAGCGGTCCCGGATTTCCCAG 
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RESULTS 
 
3.1 Purification of embryonic myoblast from Pax3GFP/+ mice 
 
To obtain a pure population of embryonic myoblasts, GFP expressing cells 
are isolated by FACS sorting from cellular suspension obtained from Pax3GFP/+ 
at E11.5 dpc. Somites and limbs were dissected so, the cells derived from the 
digestion does not contain contamination of a number of progenitor expressing 
Pax3, that could give rise a non-myogenic population. During mouse 
development at 11.5 primary myogenesis is ongoing and almost all myoblast 
present are thought to be embryonic. Approximately 1-2% of the cells obtained 
from the somites and limbs express GFP (Fig. 3.1.1 B). It was possible to sort 
20-25.000 cells from each E11.5 embryo. When reanalyzed by FACS, sorted 
populations were 95-98% pure (data not shown). To demonstrate that cells 
sorted from Pax3GFP/+ mice were indeed myogenic, immunofluorescent staining 
with antibodies specific for myogenic marker Myosin Heavy Chain (MyHC) was 
performed after 2-3 days of differentiation in vitro. Almost all (> 98%) of sorted 
cells express MyHC. Then it has been analyzed mitogen influence. As already 
published  (Biressi et al., 2007a) embryonic myoblast are not influenced by any 
kind of mitogen. The same results is obtained from primary myoblast from 
Pax3GFP/+ mouse (Fig. 3.1.1 C), in fact, it is possible to see that the 
differentiation capability is not at all influenced by TGFβ, BMP4 and bFGF, that 
from oligonucleated myotubes express MyHC like control cells. So embryonic 
myoblasts obtained from Pax3GFP/+ have the same characteristic of myoblasts 
obtained from Myf5GFP/+.. 
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Figure 3.1.1 Embryonic myoblast from Pax3GFP/+ mouse isolation 
Efficent isolation of embryonic myoblast from cellular digestion obtained from Pax3GFP/+ mice at 
day 11.5 (A,B). GFP expressing cells are separated in two dimensional plot of GFP (abscissa) 
and intrinsic SSC (ordinate). Sorted cells immediately differentiate into thin myotubes almost 
95% positive for myogenic marker (MyHC). Cells immediately after sorting are still Pax3 positive 
(B bottom panel). Embryonic myoblast insensitivity to mitogen (C) such as BMP4, bFGF and 
TGFβ. As shown in the panel cells differentiate with the same extent of control cells. Scale bar 
refers to 100um 
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3.2 Dll4 and PDGF-BB inhibit skeletal myogenesis and induce pericyte 
markers in Pax3 expressing skeletal myoblasts. 
Embryonic myoblasts, sorted from Pax3GFP/+ E11.5 embryos after removal 
of the neural tube, and a dissection of somites and limbs, were cultured in 
standard conditions (see materials and methods) that allow rapid and massive 
myogenic differentiation, with formation of thin oligonucleated, myosin heavy 
chain (MyHC)+ myotubes (Fig. 3.2.1 A). Since recent works demonstrate that 
Pax3+ cells migrate to form smooth muscle layer of dorsal aorta we address 
wheter myogenic progenitor could be able to be reprogram/recruit from 
endothelium. However, seeding sorted Pax3GFP/+ myoblasts on dishes coated 
with the Notch ligand Dll4 (responsible for pericyte recruitment during 
vasculogenesis) in the presence PDGF-BB (which receptor is present on 
embryonic myoblast) inhibited, as expected, skeletal myogenesis. Fig. 3.2.1 
B/C shows that Dll4 and PDGF-BB prevented almost completely myogenic 
differentiation and inducing, within few hours, expression of pericyte makers 
such as Alkaline Phosphatase (AP), RGS5 and NG2, undetectable in control 
cells by either qPCR (Fig. 3.2.2 A), immunofluorescence or Western Blot 
analysis (Fig. 3.2.1 A-C). Among the other pericyte markers, PDGF Receptor B 
was expressed in myoblasts but its expression increased two fold after 
exposure to Dll4 and PDGF-BB (Fig. 3.2.2 A central panel). Western Blot did 
not detect this receptor in myoblasts, possibly because of post-transcriptional 
regulation (Fig. 3.2.1 C). Both qPCR and Western blot analysis (Fig. 3.2.2 A, 
3.2.1 C) revealed an enhanced expression of Myf5 at variance with all the other 
myogenic markers tested, which have been strongly downregulated. Moreover, 
if myogenic markers are immediately downregulated, in the first hours of 
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culture, pericytes marker up-regulation appears at the end of the culture. 
Exposure to Dll4 and PDGF-BB did not interfere with the low level of apoptosis 
observed (<5% data not shown) while treated cells continued to proliferate (Fig. 
3.2.2 B). Dll4 and PDGF-BB-dependent inhibition of myogenesis was found to 
be not reversible after subculture in fresh, control medium (data not shown). 
However, inhibition of Notch signaling using a γ-secretase inhibitor (that blocks 
proteolytic activation of Notch receptors, preventing nuclear translocation of the 
intracellular domain in Pax3GFP/+, Dll4 and PDGF-BB treated cells, caused rapid 
and massive myogenic differentiation (Fig. 3.2.1 A/B, bottom line), leading to 
the formation of multinucleated myotubes. Reversion is also confirmed by 
qPCR analysis (Fig. 3.2.2 A) So embryonic myoblast commonly insensitive to 
any kind of mitogen, are sensitive to Notch signaling, and more interesting it 
appear that after Notch up-regulation, myogenic cells loose their myogenic 
capacity to acquire a pericyte property. 
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Figure 3.2.1 Characterization of embryonic myoblast treated with Dll4 and PDGF-BB 
Immunofluorescence analysis of marker express by PaxGFP/+ sorted cells. Cells differentiate 
immediately after sorting (A upper panel). After exposure to Dll4 and PDGF-BB embryonic 
myoblast do not differentiate and start to express pericytes markers. (A second and third panel). 
In (B) it is possible to see morphology of sorted cells and the expression of alkaline phospatase. 
Cells treated with Notch inhibitor (Υ-secretase) restore myogenesis (A bottom panel) and 
downregulate pericytes markers. (C) Western Blot analysis confirmed the data of 
immunofluorescence where myogenic markers are downregulate with the exception of Myf5, 
while pericytes marker are all upregulate. Scale bar refers to 100 um. 
 
 
 
Figure 3.2.2 qPCR analysis of sorted embryonic myoblast 
(A) qPCR analysis perform on Pax3GFP/+ sorted cells, in control conditions, with Dll4+PDGF-BB 
and with γ secretase inhibitor (L-685-458). All the analysis were normalized with an embryo at E 
11.5. Relative mRNA analyzed was for MyoD, Myf5, Myogenin and MyHC to detect myogenic 
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differentiatio, while for pericytes NG2, AP, RGS5 and PDGFRβ were tested. mRNA was 
analyzed in control cells, cells treated with Dll4 and PDGF-BB and cells treated, after Dll4 plus 
PDGF-BB with γ-secretase inhibitor, that restores myogenesis. Scale bar represent means of n 
9 experiments ± s.d was tested using one-way ANOVA analysis of variance followed by 
Bonferroni multiple comparison post-test. A probability of less than 5% (P < 0.05) was 
considered to be statistically significant. (B) Growth curve of control cells compared to cells 
treated with Dll4 and PDGF-BB. Cells, beside normal behavior, go on proliferating and it is 
possible to culture them despite control one that does not proliferate and terminal differentiate 
immediately. 
 
Figure 3.2.3 NOTCH ligands influence 
(A) Left panel; Pax3GFP/+ sorted cells, plated on Dll4 plus PDGF-BB and stained for alkaline 
phosphatase (AP) reaction, after 3 days of culture. Middle panel; Pax3GFP/+ sorted cells plated 
on Dll1 plus PDGF-BB and stained for alkaline phosphatase (AP) after 3 days of culture. It is 
possible to see that no cells express AP. Right panel; Pax3GFP/+ sorted cells plated on 
JAGGED1 plus PDGF-BB and stained for alkaline phosphatase (AP) after 3 days of culture. 
Also here none of the cells express AP. All cells in this experiment belong from the same 
sorting. Scale bar refers to 100um. 
 
To then test specificity of Dll4, we repeated the same experiment using 
other Notch activators such as Dll1 and Jagged1.  As expected, Pax3 
expressing myoblasts did not differentiate in the presence of Dll1 and Jagged1; 
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It is in fact known that also Jagged1 is involved in pericytes recruitment.(Liu et 
al., 2009) .However under these different conditions, treated cells did not 
activate expression of pericyte markers (Fig. 3.2.3 A), indicating that this effect 
is specific only for Dll4 and not redundant among the other Notch ligands 
tested. The only effect that is possible to see is myogenesis inhibition that is 
expected once Notch is activated. 
3.3 Dll4 and PDGF-BB also reprogram Myf5 expressing myogenic cells. 
Although Pax3 expression marks early myogenic commitment in the 
embryo, cells entering myogenic differentiation pathway activate bHLH such as 
Myf5 and/or Myod (Buckingham and Relaix, 2007). Therefore we investigated 
whether Dll4 and PDGF-BB could also reprogram Myf5 expressing cells that are 
more committed than Pax3 to myogenesis. To this aim we FACS-sorted from 
the Myf5GFP/+ mouse embryonic (E11.5) and fetal (E16.5) myoblasts as already 
publish(Biressi et al., 2007b). Under the same experimental conditions 
previously employed for Pax3-GFP expressing myoblasts, (Fig. 3.3.1 A-B) 
Myf5-GFP expressing myoblasts were also inhibited to differentiate, with fetal 
myoblast much more sensitive to Notch activation, although the frequency of 
reprogramming was lower than in Pax3-GFP positive myoblasts, with 
approximately 50% of cells that up-regulated AP (Fig 3.3.1 C bottom panel) and 
other pericyte markers (data not shown).  So this in vitro reprogramming Notch 
driven works, in less extent, also in more committed myogenic cells. 
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Figure 3.3.1 Embryonic and fetal myoblast sorted from a Myf5GFP/+ mouse 
Efficent isolation of embryonic and fetal myoblast from cellular digestion obtained form Myf5GFP/+ 
mice at E11.5 (B left panel) and E16.5 (B right panel). (C) Right upper panel: efficient 
differentiation of embryonic myoblast in phase contrast and stained for MyHC (in red). Left 
upper panel: efficient differentiation of fetal myoblast in phase contrast and stained with 
MyHC.(C) Left bottom panel: influence of Notch ligands, Dll4 plus PDGF-BB on embryonic 
myoblast. As is possible to see, cells does not differentiate and express alkaline phosphatase 
and do not express MyHC. Right bottom panel: influence of Notch ligands, Dll4 plus PDGF-BB 
on fetal myoblast. As is possible to see, cells does not differentiate and express alkaline 
phosphatase, even in a major extent than embryonic one, due to the higher sensitivity of this 
cells to mitogen, and do not express MyHC. Scale bar refers to 100um. 
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3.4 Dll4/PDGF-B treated myoblasts associate with endothelial cells to form 
vessel-like networks in vitro and in vivo. 
We then tested the ability of myoblasts, exposed to Dll4 and PDGF-BB to 
form a vessel-like structure in vitro and in vivo (Fig. 3.4.1 A-C). This because to 
assess that a cells become a pericytes it is important that it express not only 
pericytes marker, but also to assolve to pericyte function, such as vessel 
stability and formation. Human Umbilical Vein Endothelial Cells (HUVEC) 
cultured alone in matrigel, normally formed a network that disappeared after few 
days (not shown). When coculterd with them, untreated Pax3-GFP positive cells 
formed thin oligonucleated myotubes in matrigel mainly away from HUVECs, 
indicating that they readily differentiate into skeletal muscle also under this 
experimental condition (Fig. 3.4.1 A upper lane). Only when Pax3-GFP positive 
cells, were previously treated with Dll4 and PDGF-BB, and cultured in matrigel 
together with unlabeled HUVECs, they closely associated to them and formed a 
vessel-like network that remained stable for up to two weeks (Fig. 3.4.1 A 
bottom lane). The same effect was observed when matrigel plug was implanted 
subcutaneously into nude mice: after two weeks a large vessel network, 
connected with the host vasculature had developed (Fig. 3.4.1 B). 
Immunofluorescence analysis confirmed close association of Pax3-GFP 
positive cells with HUVEC labeled by an anti-BV9 (specific for human 
endothelial cells) antibody in red (Fig. 3.4.1 C). This association and vessel 
stability, clearly demonstrate that Pax3-GFP positive cells, previously treated 
with Dll4 and PDGF-BB, are able to mimic pericyte function and behaviour; 
however, from the coculture it’s possible to appreciate also the morphology and 
localization of the cells that, closely associated to vessel, stabilize endothelial 
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network avoiding its disruption. In conclusion, Notch activation in embryonic 
myoblast drives them not only to the expression of quite all of pericytes marker 
but also to their functional activity and localization. 
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Figure 3.4.1 In vitro and in vivo angiogenesis assay 
Example of a matrigel sandwich (in vitro) with HUVEC cells and control cells (A, upper and 
lower panel respectively). Cells are stained with MyHC antibody (red) and Hoechst (blue). 
Matrigel sandwich with previously treated cells Dll4 and PDGF-BB mixed with HUVEC cells. 
Phase contrast shows a stable endothelial network and it is possible to see the vessel tube (B). 
Cells are stained for GFP (green) and BV9 (red) that mark Human endothelial cells. (B) Scheme 
of a matrigel plug in vivo under the skin of nude mice. Plug is composed of Dll4 plus PDGF-BB 
treated cells mixed with HUVEC. (C) Confocal analisys of matrigel plug: cells are stained for 
GFP (green) and BV9 (red). Scale ber refers to 100um. 
 
 3.5 Committed skeletal myoblasts can be reprogrammed during in vivo 
development. 
3.5.1 E11.5  MyoDiCRE:RosaNICD  
RosaNICD  (Murtaugh and Melton, 2003) transgenic mice express the Notch 
IntraCellular Domain (NICD) and thus activate the Notch pathway after Cre 
recombination. We crossed RosaNICD with MyoDiCre mice (Kanisicak et al., 2009) 
so all cells that begin to express MyoD will also activate Notch. Although it is 
well know that Notch inhibits myogenesis, its activation during in vivo skeletal 
myogenesis had not been previously investigated; more importantly, we wanted 
to know whether Notch activation would induce a pericyte phenotype also in 
vivo. As expected, E9.5 double transgenic embryos appeared to be normal 
(data not shown), consistent with the notion that the early myotome is formed 
under the transcriptional control of Myf5, before MyoD activation (Cossu et al., 
1996; Kanisicak et al., 2009). On the other hand at E11.5 however, 
MyoDiCRE:RosaNICD embryos appeared to be smaller and showed an edema, 
more pronounced in the back; hind and forelimbs appeared to be 
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underdeveloped (Fig. 3.5.1 A). At this stage expression of myogenic markers 
appeared reduced (though differences were not statistically significant), with the 
exception of Myf5, whereas pericyte markers showed no variations in 
expression with the exception of an upregulation of AP that usually start to be 
express in the embryo around vessel not before E13.5/14.5 (Ugarte et al., 
unpublished observation) (Fig. 3.5.1 B). Also Western Blot analysis did not 
show major differences (Fig. 3.5.1 C). At the histological level no major 
differences were observed (Fig. 3.5.1 D, upper panel) but immunofluorescence 
analysis revealed reduced MyHC+ cells in the limbs (arrows in Fig. 3.5.1 D, 
bottom panel), although the myotomes appeared to be similar. Higher 
magnification immunoflurescence of the trunk mesoderm revealed Myf5+ and 
SMA (smooth muscle actin) cells in both WT and MyoDiCREROSANICD embryos, 
but widespread expression of AP was only detected in MyoDiCREROSANICD 
embryo and not in WT (Fig. 3.5.1 E upper panel), where it usually appears only 
around small vessels at E13.5 (Ugarte et al. unpublished observations). 
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Figure 3.5.1 E 11.5 MyoDiCRE:ROSANICD analysis 
Morphology of MyoDiCRE:ROSANICD mice and WT at E11.5.qRT analysis on WT and 
MyoDiCRE:ROSANICD. Relative mRNA analysis of MyoD Myf5 MyHC and Myogenin to teste 
myogenesis and NG2, RGS5, AP, PDGFR for pericytes. Western blot analysis of myogenic 
(Myf5, MyHC) and pericyte (PDGFR, NG2, AP) marker expressed by WT embryo and and 
MyoDiCRE:ROSANICD. H&E staining on serial tranverse sections of whole embryo (upper panel 
part). Immunofluorescence on serial tranverse section of whole embryo stained with MyHC (red) 
and PECAM (green).Immunofluorescence on serial transverse sections of hindlimb stained with 
Myf5 (green), AP(red) and PECAM(violet) in the upper part of the panel; in the lower part 
sections are stained with Myf5 (green) SMA (red) and PECAM (violet). Scale bar refers to 
100um. 
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3.5.2 E13.5 MyoDiCRE:RosaNICD  
At E13.5 a similar phenotype was exacerbated in mutant embryos (Fig. 
3.5.2 A); also edema in mutant embryos became bigger while the embryos is 
still smaller; but now differences in gene and protein expression start to be 
statistically significant (Fig. 3.5.2 B-E) while the reduction of MyHC positive 
fibers appeared to be dramatic (Fig. 3.5.2 D, bottom panel). In Fig. 3.5.2 D 
bottom panel, it is possible to see how the morphology starts to be 
compromised: MyHc is express only in the heart and there is no development of 
any muscle. Also the embryos dimension is different. Myf5 expressing cells 
increase remarkably, this without leading to any terminal differentiation. 
Confocal microscopy confirmed close association of Myf5 expressing cells with 
the endothelium and medium and small size vessel, while, in WT embryos, 
Myf5 expression start to decrease, and SMA positive cells are detactable, 
anyway, Myf5 positive cells localize far from vessel. Real time analysis of 
myogenic marker reveal the statistic significant of the decrement in the 
MyoDiCRE:RosaNICD despite the WT (Fig 3.5.2 B). Moreover, pericyte markers 
expression is not significant meaning that to reprogram cells fate in an embryo 
probably take more developmental stages. 
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Figure 3.5.2 E 13.5 MyoDiCRE:ROSANICD analysis 
 (A) Morphology of MyoDiCRE:ROSANICD and WT mice at E13.5. (B) qRT analysis on WT and 
MyoDiCRE:ROSANICD. Relative mRNA analysis of MyoD Myf5 MyHC and Myogenin to test 
myogenesis and NG2, RGS5, AP, PDGFR for pericytes. (C) Western blot analysis of myogenic 
(Myf5, MyHC) and pericyte (PDGFR, NG2, AP) marker expressed by WT embryo and 
MyoDiCRE:ROSANICD. (D) H&E staining on serial transverse section of whole embryo (upper 
panel part). (E) Immunofluorescence on serial transverse section of whole embryo stained with 
MyHC (red) and PECAM (green).Immunofluorescence on serial transverse sections of hindlimb 
stained with Myf5 (green), AP(red) and PECAM(violet) in the upper part of the panel; in the 
lower part sections are stained with Myf5 (green) SMA (red) and PECAM (violet). Scale bar 
refers to 100um. 
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3.5.3 E16.5 MyoDiCRE:RosaNICD  
At E16.5, mutant fetuses were severely compromised, with very large 
edema in the back (Fig. 3.5.3 A), dramatically reduced skeletal muscle 
differentiation, and dimension of the fetus and development compromise. 
Looking at the marker of skeletal muscle differentiation is possible to appreciate 
either by q-PCR (Fig. 3.5.3 B), Western Blot (Fig. 3.5.3 C), histology and 
immunofluorescence a strong downregulation (Fig. 3.5.3 D). Exactly like in vitro, 
Myf5 expression appeared three-fold increased (Fig. 3.5.3 B) and was clearly 
detected by immunofluorescence, whereas it appeared fainter in WT embryos 
where it is known to decline at this stage of development. (Ott et al., 1991) 
At E16.5 the development did not proceeded further, lung formation was 
impaired, and the edema became even more severe (Fig. 3.5.3 A). A similar 
phenotype was reported for the Myf5/MyoD double mutant embryos (Rudnicki 
et al., 1993)Here a large percentage of Myf5 expressing cells is associated to 
vessel as it possible to see in the confocal analysis at higher magnification. Also 
all pericytes markers analized are strongly up-regulated and, by qPCR, 
statistically significant (Fig 3.5.3 B). Moreover, by immunoflurescence is clear 
the AP is express in a large extent in cells that never express it as it’s clear in 
Fig 3.5.3 E right panel. This means that during ongoing of development cells 
that activate Notch and inhibit myogenesis assume another fate with another 
localization and marker expression, exactly like in vitro results. 
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Figure 3.5.3 E 16.5 MyoDiCRE:ROSANICD analysis 
 (A) Morphology of MyoDiCRE:ROSANICD and WT mice at E16.5. (B) qRT analysis on WT and 
MyoDiCRE:ROSANICD. Relative mRNA analysis of MyoD Myf5 MyHC and Myogenin to test 
myogenesis and NG2, RGS5, AP, PDGFR for pericytes. (C) Western blot analysis of myogenic 
(Myf5, MyHC) and pericyte (PDGFR, NG2, AP) marker expressed by WT embryo and 
MyoDiCRE:ROSANICD. (D) H&E staining on serial transverse section of whole embryo (upper 
panel part). (E) Immunofluorescence on serial transverse section of whole embryo stained with 
MyHC (red) and PECAM (green).Immunofluorescence on serial transverse sections of hindlimb 
stained with Myf5 (green), AP(red) and PECAM(violet) in the upper part of the panel; in the 
lower part sections are stained with Myf5 (green) SMA (red) and PECAM (violet). Scale bar 
refers to 100um. 
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3.5.4 E18.5 MyoDiCRE:RosaNICD  
At E18.5 fetus’ morphology is completely compromise (Fig. 3.5.4 A). The 
dimension are completely different from WT there are no muscles formation and 
the edema is very pronounced in the back. Hind and forelimb are strongly under 
developed. Looking at the qPCR (Fig 3.5.4 B) is clear, by the significance of the 
statistical analysis that myogenesis didn’t occur, and pericytes marker 
expression is stronger (Fig 3.5.4 B). In fact, looking at the immunofluorescence 
is immediately clear the difference: in the MyoDiCRE:RosaNICD Myf5 expression is 
three fold increase than the wild type, where, as usual, Myf5 is not express 
anymore. Western Blot principally confirmed results of qPCR (Fig 3.5.4 C-E). 
Looking deeper at the morphology is it possible to see that the diaphragm is 
under developed and also, for this reason lungs are not terminally differentiated; 
this leads to the impossibility to breathe, and so new born mice died 
immediately. All these morphological analysis confirm the active role played by 
Notch during development; in fact Notch is responsible not only for the lineage 
determination during dermamyotome development (Esner et al., 2006) but also 
for recruitment of pericytes by tip cells. This data show the evidence that also a 
committed myogenic cell under suitable stimulus is prone to be reprogram to 
another fate. 
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Figure 3.5.4 E 18.5 MyoDiCRE:ROSANICD analysis 
 
(A) Morphology of MyoDiCRE:ROSANICD and WT mice at E18.5. (B) qRT analysis on WT and 
MyoDiCRE:ROSANICD. Relative mRNA analysis of MyoD Myf5 MyHC and Myogenin to test 
myogenesis and NG2, RGS5, AP, PDGF for pericytes. (C) Western blot analysis of myogenic 
(Myf5, MyHC) and pericyte (PDGFR, NG2, AP) marker expressed by WT embryo and 
MyoDiCRE:ROSANICD. (D) H&E staining on serial transverse section of whole embryo (upper 
panel part). (E) Immunofluorescence on serial transverse section of whole embryo stained with 
MyHC (red) and PECAM (green).Immunofluorescence on serial transverse sections of hindlimb 
stained with Myf5 (green), AP(red) and PECAM(violet) in the upper part of the panel; in the 
lower part sections are stained with Myf5 (green) SMA (red) and PECAM (violet). Scale bar 
refers to 100 um. 
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3.6 Pericytes localization in WT embryos at E13.5 
After mutant embryos and fetus analysis, following step has been to know 
wheter during normal embryos/fetus development myogenic cells could be 
reprogram by endothelium upon necessity of vasculogenesis. So in WT 
embryos we analyzed cells closely adjacent to vessel that are likely to be 
pericytes. Two different WT mice have been used. The first was a WT (Fig. 6 A-
D) where, like a very rare event, happen that some myogenic cells closely 
associate to vessel and express pericytes maker like SMA and NG2. (Fig 3.6.1 
A-D). Then we crossed a MyoDICRE: ROSAEYFP or MyoDICRE: ROSA26R to trace 
MyoD positive cells localization. 
In Fig 3.6.1 E-K it’s possible to see cells that expressed MyoD (in green, 
YFP and in blue X-gal) associate to vessel. In Fig 3.6.1 F we show the correct 
localization of myogenic cells. In Fig 3.6.1 I also is possible to see that YFP 
positive cells also express NG2. The last panel (Fig 3.6.1 K) is a confocal 
analysis revealing the connection of myogenic cells with vessel wall. These 
data clearly confirm the in vivo data illustrated before; the phenomenon we 
described with a mutation (by activation Notch pathway in already committed 
myogenic cells) is present also during natural development of WT type embryo 
meaning that myogenesis and vasculogenesis are two pathways which 
signaling compete to recruit cells. Once a cell enter myogenic program could 
have the possibility to be reprogram by a signaling originating from 
endothelium. 
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Figure 3.6.1 Marker analysis on WT mouse 
Immunofluorescence analysis on serial transverse section of WT mouse embryo at E13.5. 
Section is stained for SMA (green) Myf5 (red) and Hoechst (blue). Immunofluorescence 
analysis on serial transverse section of WT mouse embryo at E13.5. Section is stained for SMA 
(green) Myf5 (red) and Hoechst (blue). Immunofluorescence analysis on serial transverse 
section of WT mouse embryo at E13.5. Section is stained for SMA (green) Myf5 (red) and 
Hoechst (blue) Immunofluorescence analysis on serial transverse section of WT mouse embryo 
at E13.5. Sections represent a trasversal section of a vessel. Section is stained for Myf5 (green) 
NG2 (violet) and PECAM (red). Immunoistochemistry of a transversal section of a vessel from 
MyoDiCRE:ROSA26R at E13.5.Lacz staining indicates MyoD positive cells around a vessel stained 
with PECAM for peroxidase. Immunofuorescence of a transversal section from 
MyoDiCRE:ROSAEYFP at E13.5. Section is stained for PECAM (red) and YFP (green). 
Immunofuorescence of a transversal section from MyoDiCRE:ROSAEYFP at E13.5. Section is 
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stained for PECAM (red) and YFP (green). Immunofuorescence of a transversal section from 
MyoDiCRE:ROSAEYFP at E13.5. Section is stained for PECAM (red) and YFP (green). 
Immunofuorescence of a transversal section from MyoDiCRE:ROSAEYFP at E13.5. Section is 
stained for PECAM (red) YFP (green) NG2 (violet) and Hoechst (blue). Immunofuorescence of 
a transversal section from MyoDiCRE:ROSAEYFP at E13.5. Section is stained for PECAM (red) 
YFP (green) and Hoechst (blue). Immunofuorescence of a transversal section from 
MyoDiCRE:ROSAEYFP at E13.5. Section is analyzed with confocal microscope. It is stained for 
PECAM (violet) Myf5 (green) and AP (red). Scale bar refers to 100um. 
3.7 Notch induced up-regulation of ID3 inhibiting Myf5 ability to activate 
myogenesis   
Dll4 in vitro and MyoDiCRE:ROSANICD in vivo up-regulate Notch3 and 
Notch1 expression that, as expected, leads to a strong down-regulation of 
MyoD, and MyHC expression. Unexpectedly, Myf5 expression was robustly 
upregulated, possibly as an attempt to compensate for the absence of MyoD. 
However Myf5, despite its high level of expression (Fig.3.2.1; Fig 3.5.1; Fig 
3.5.2 Fig 3.5.3 Fig 3.5.4), was not sufficient to drive terminal myogenic 
differentiation. Notch it is known to induce upregulation of Id factors that may 
interfere better with MyoD but, in its absence, also with Myf5 activity (Langlands 
et al., 1997). As a consequence we investigated whether Myf5 protein may form 
a complex with Id3 (the most up-regulated member of the family after Notch 
activation) (Fig 3.7.1 left panel) and thus become unable to bind Myogenin 
promoter and trigger myogenesis. To test this possibility immunoprecipitation 
assays were conducted which revealed binding of the Myf5 and ID3 in vivo, 
thus providing a possible explanation for the inability of Myf5 to activate 
myogenesis . 
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Figure 3.7.1 Expression analysis of Notch3 and Id3 
(A) Relative mRNA analysis of ID3 and Notch3 in not treated embryonic myoblasts, embryonic 
myoblast treated with Dll4 and PDGF-BB and in embryonic myoblast reverted with γ-secretase 
inhibitor.  
3.8 Model of Notch signaling activity in myogenesis 
 
Notch pathway is responsible for lineage determination in 
dermamyotome.(Esner et al., 2006). Since during development exist a sort of 
competition between different lineages to recruit cells, Notch signaling is the 
best candidate for this role. In fact, cells that are attracted to endothelium by tip 
cells, are likely to be myoblast. The molecule secrete by endothelial tip cells is 
Dll4, so, in the model, is clear that Notch activation turn off myogenic genes, 
and activate pericytes ones. Which are these pericytes genes is still not publish. 
Notch activation also up regulated Id genes (1,2,3) and Twist, which are able to 
bind MyoD and Myf5. Since MyoD is immediately down regulated after Notch 
activation, Myf5 binds to Id3 and this way cannot trigger myogenesis (Fig 3.8.1)  
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Figure 3.8.1 Model 
Possible model of molecular mechanism underneath Notch signaling action to determine cells 
fate.  
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DISCUSSION 
Pericytes are still poorly defined cells with multiple embryonic origins 
(mesenchyme, neural crest in certain anatomical districts and, suggested but 
not yet demonstrated, trans-differentiation of endothelial cells). They express a 
number of markers, none of which is unique and, moreover, not all mar;kers are 
expressed simultaneously in the same cell, making their identification in vivo 
and their prospective isolation difficult task (Armulik et al., 2011). In contrast, 
myogenic cells have been thoroughly characterized and are unequivocally 
identified by the expression of a number of unique (MyoD, Myf5, MRF4) or 
restricted (Pax3, Pax7) transcription factors (Rudnicki et al., 2008); whereas 
their surface markers are often shared with other cells types, with the possible 
exception of integrin alpha7. (Burkin and Kaufman, 1999; Conboy and Rando, 
2002) 
Notch and its ligands are involved in virtually any process during tissue 
development and regeneration. (Andersson et al., 2011; Dahlqvist et al., 2003) 
In the case of blood vessels, Dll4 and PDGF-BB secreted from tip cells of 
growing vessels, respectively bind Notch and PDGF receptor β on surrounding 
mesoderm cells, in order to recruit them to a pericyte fate and thus building the 
outer layer of the maturing vessel.(Hellstrom et al., 1999) In developing skeletal 
muscle, mesoderm tissue contains many skeletal myoblasts at different stages 
of proliferation, commitment and differentiation.  It is thus conceivable that 
myoblasts, if exposed to recruiting signals from the endothelium, may change 
their fate and enter the pericyte lineage. Indeed, while embryonic myoblasts are 
insensitive to most mitogens (Biressi et al., 2007b) they are inhibited only by 
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Notch ligands. Intriguingly, all the Notch ligands tested, i.e. Dll1, Dll4 and 
Jagged1 are able to suppress expression of myogenic genes (with the notable 
exception of Myf5) but only Dll4 activates pericyte genes in committed, Pax3, 
Myf5 or MyoD expressing myoblasts. Moreover myogenic cells, exposed to Dll4 
and PDGF-BB in vitro adopt a perithelial position stabilizing vessel-like 
networks of endothelial cells in matrigel plugs both in vitro and in vivo. Finally, if 
NICD (Notch Intracellular Domani) is selectively activated during embryonic 
development in cells expressing MyoD, these cells silence myogenic genes 
(again with the exception of Myf5) and express pericyte markers. Whenever 
they come close to a vessel, they adopt a perithelial position and still maintain a 
strong Myf5 expression. Under these experimental conditions, we uncover and 
amplify in myogenic cells a not frequent but detectable event that occurs during 
normal embryogenesis, where both Myf5 expressing and MyoDiCRE labeled cells 
are found inside the vessel wall, expressing pericyte markers. 
Thus, it appears that endothelial cells can directly reprogram myogenic 
cells to a pericyte fate and this environmental reprogramming depends upon 
exposure to Dll4 and PDGF-BB (that however can mimic endothelial cells 
action), likely as a consequence of physical proximity to vessel during tissue 
histogenesis. This reprogramming does not erase myogenic identity for two 
reasons: firstly, in vitro γ-secretase inhibitor restores terminal myogenic 
differentiation; secondly, Myf5 continues to be expressed in vitro and in vivo at 
levels much higher than WT, even though it fails to drive terminal differentiation. 
Notch downstream effectors Hairy and Hes1 are known to activate myogenic b-
HLH inhibitors such as Twist and Id. We confirm here that indeed all of these 
genes are up-regulate in myogenic cells exposed to Dll4 (with the exception of 
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Id2). (Langlands et al., 1997; Reynaud-Deonauth et al., 2002)Among these, Id3, 
the most strongly upregulated gene, binds to Myf5, thus preventing its ability to 
bind and activate the Myogenin promoter.  
In addition, it should be considered that both endothelial, smooth and skeletal 
muscle progenitors originate in the dermomyotome during somitogenesis and 
fate choice at that time is dictated by signaling molecules such as BMP, TGFβ 
and Notch. (Ben-Yair and Kalcheim, 2008; Esner et al., 2006; Lagha et al., 
2009; Vieira et al., 2004) Moreover, Pax3 expressing myogenic precursors are 
able to migrate ventrally to built the smooth muscle of the aorta and express 
smooth muscle-specific genes.  We now show that signaling molecules act also 
at later stages of development and are able to drive reprogramming (fate 
change from skeletal to future smooth muscle) also in committed cells.  
Thus, it appears that during embryogenesis cells adopt a specific fate 
depending upon the timely appropriate exposure to signaling molecules 
emanating from surrounding cells. However, these fate choices are not 
irreversibly fixed but are reinforced and stabilized by the microenvironment. 
Experimental or natural exposure to different signals can still reprogram cells to 
a different (though embryologically related) fate; transcription factor-dependent 
in vitro reprogramming may simply reflect the experimental activation, at 
obviously higher frequency, of intra-cellular pathways also activated by 
signaling molecules. In the case of developing skeletal muscle, developing 
fibers and endothelium may compete for surrounding mesoderm cells, whose 
final fate is irreversibly fixed only at the onset of terminal differentiation. 
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